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Purpose: The purpose of this compendium is to identify strategies that influence health 
outcomes of persons with sickle cell disease (SCD) by investigating available pain instruments, 
current use of genetic testing to personalize therapies, and the associations of psychosocial 
characteristics with quality of life. 
Problem: Suboptimal care for patients with SCD is associated with non-comprehensive pain 
assessment instruments, limited use of available genetic tests to prescribe the potentially most 
effective pharmaceuticals in a personalized plan of care, and the absence of national evidence-
based guidelines for the psychosocial care of this population. 
Approach: The research designs used were an integrative review with a 
biopsychosocial-religiosity/spirituality (BPS-R/S) framework, a literature review using Diffusion 
of Innovation as a framework, and a quantitative study guided by the Theory of Self-Care 
Management for Sickle Cell Disease using secondary analysis. 
Findings: The integrative review suggested that pain control outcomes might be improved by 
incorporating biopsychosocial-religiosity/spirituality measures to the pain instruments. The 
literature review indicated that the use of available genetic tests to determine the efficacy of 
pharmaceutical treatment options might lead to personalized care in the person with SCD. The 
secondary analysis found that the association between psychological factors and quality of life in 
the SCD sample was significant and suggested that randomized controlled trials be conducted to 
confirm findings prospectively.  The overall findings identified that persons with SCD have 
complex needs inherent in a disease process that affects all body systems. Pain is the hallmark 




Conclusion: BPS-R/S and genetic domains contribute to humanistic care and may benefit 
persons with SCD. Persons with SCD may experience improved health outcomes when the 
biopsychosocial- religiosity/spirituality dimensions are supported by services in the healthcare 
environment. The implementation of these findings through researcher, provider, patient, and 
family education may improve health outcomes and quality of life. 
Key words: Pain, sickle cell, measurement, instruments, validity, biopsychosocial, religiosity, 
spirituality, cytochrome P450, pain, pharmacogenomics, genetics, genomics, nursing, 
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Sickle Cell Compendium Introduction 
Lori L. Johnson Vick 




Sickle Cell Compendium Introduction 
Sickle cell disease (SCD) is the most common genetic blood disorder in the United States 
(National Library of Medicine [NLB], 2015b).  It is categorized as an autosomal recessive 
genetic group of disorders, with 1000 newborns diagnosed each year (Sickle Cell Disease 
Association of America [SCDAA], 2015).  Persons with SCD are typically descendants of 
African, Mediterranean, Arabian, East Indian, South American, Central American, or Caribbean 
origin (Piel, et al., 2010; U.S. Department of Health and Human Services [USDHHS], 2011).  
Surveillance measures continue to be challenging, and precise prevalence of SCD has not been 
determined (Centers for Disease Control & Prevention [CDC], 2012a; 2012b).  Current estimates 
are that 70,000 - 100,000 persons are affected in the U.S., and millions of persons are affected 
globally (USDHHS, 2014).  In the U.S., stakeholders include persons with SCD, approximately 
2-3 million people living with sickle cell trait (SCT), family members, communities of interest 
(local, regional, and national sickle cell organizations), employers, health care providers, 
researchers, insurers, and government agencies (USDHHS, 2011; USDHHS, 2014).  This 
dissertation compendium explores three components examining factors of one topical area 
affecting the lives of persons with sickle cell disease (SCD): (a) Integrative Review of Pain 
Instruments, (b) The Application of Genomic Testing for Pain Management, and (c) Associations 
of Psychosocial Measures with Quality of Life in a Sample of Adults with Sickle Cell Disease 
(Table 1). 
Background 
In persons unaffected by SCD, erythrocytes (red blood cells [RBCs]) are highly flexible 
biconcave disc-shaped cells that make up 42-45% of blood volume. Each normal RBC has a 120-
day life cycle.  Blood contains around 5 million RBCs per cubic millimeter.  Each RBC consists 
of 200-300 million molecules of hemoglobin.  Hemoglobin (Hb) transports oxygen and carbon 
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dioxide throughout tissues and facilitates the maintenance of blood pH balance (Patton & 
Thibodeau, 2013). 
In persons affected by SCD, RBCs sickle as a result of a single mutation of the 
hemoglobin beta gene (HbB) located in the short arm of chromosome 11 at position 15.5.  HbB 
provides the genetic code for the protein beta globin, which makes up 2 of the 4 subunits of 
hemoglobin (NLM, 2015a).  In one SCD mutation, glutamic acid is replaced with valine, 
changing the beta globin subunit and creating significant consequences.  This mutation produces 
abnormalities of the hemoglobin’s molecular structure that result in rigidly sickled cells, an 
erosion of the cells’ functional attributes, and a disruption in their normal longevity from 120 
days to about 20 days.  These sickled cells have a tendency to adhere to the vascular endothelial 
membrane, causing painful vaso-occlusive episodes (VOEs), tissue ischemia, inflammation, and 
organ damage (Ballas, et al., 2010; Bender & Douthitt Seibel, 2014; Northen, 2008).  This 
cascade of pleiotropic and biological events triggers potentially fatal physiological pathologies 
affecting the psychological and social dimensions of persons with SCD (Ballas et al., 2010; 
Engel, 1977; Thomas, Stephenson, Swanson, Jesse, & Brown, 2013). 
Mortality Factors 
In 1973, the median age of death in persons with SCD was just over 14 years according 
to a seminal study based on autopsies (Diggs, 1973).  In the following 2 decades, survival rates 
increased to 20 years (Platt et al., 1994). Neonatal testing, improvements in health education, and 
preventive measures have resulted in fewer early deaths and longer average life spans in persons 
with SCD (Telfair, Alexander, Loosier, Alleman-Velez & Simmons, 2004).  Preventive measures 
include vaccinations, antibiotic in the first 5 years of life,  the use of Hydroxyurea to increase 
fetal hemoglobin, and transcranial Doppler and packed red blood cell transfusions as stroke 
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management strategies (Hankins et al., 2014: Hussain, Nichols, Bowman, Xu, & Neunert, 2015; 
Ware et al., 2011).  A more recent study examining 16,654 sickle cell deaths from 1979-2005 
reported that the median age at death was 42 years for women and 38 years for men (Lanzkron, 
Carroll, & Haywood, 2013). 
Due to the median age increase, adults with SCD require new strategies to improve their 
health outcomes and promote quality of life throughout their lifespan. Health management 
strategies therefore should encompass pain control and health-related factors. 
Morbidity Factors 
Pain. Pain is the hallmark symptom of SCD, and coordinated care planning for pain 
management is of primary importance (United States Department of Health [USDH], 2002; 
USDHHS, 2014).  The health care needs of persons with SCD vary throughout their lives.  
Patients with SCD experience both chronic and acute pain (Ballas et al., 2010; Taylor, Stotts, 
Humphreys, Treadwell, & Miaskowski, 2013).  In early adulthood, individuals with SCD 
experience increased incidences of acute pain resulting in hospitalization for VOEs or pain crises 
(Jenerette & Brewer, 2010; Serjeant, 1997), increased physical disability, and difficulty 
maintaining or getting employment due to frequent hospitalizations. 
System-related factors.  SCD can affect every organ system (Ballas et al., 2010).  In 
addition to VOEs, adults with SCD may experience acute renal failure (ARF), priapism, 
hepatobiliary complications, acute and chronic anemia, splenic sequestration, acute chest 
syndrome (ACS), avascular necrosis, pulmonary hypertension, and many other complications 
(USDHHS, 2014). 
Neurocognitive factors.  As individuals with SCD mature, they have an increased risk of 
age-related cognitive decline (Vichinsky et al., 2010).  Age-related decline, chronic anemia, and 
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ischemic or hemorrhagic events associated with SCD may play a significant role in 
neurocognitive impairment. 
Psychosocial factors.  Disease burden, frustrations, and stigma increase the likelihood of 
psychosocial problems including depression (Edwards et al., 2009; Jenerette & Brewer, 2010; 
Jenerette, Funk, & Murdaugh, 2005). Depression in persons with SCD often goes unidentified 
and unmanaged (USDH, 2002).  Poor communication and patient stigmatization have resulted in 
perceived maltreatment and lack of trust in the provider-patient relationship (Jenerette & Brewer, 
2010; Haywood et al., 2010) and may factor into psychosocial concerns affecting patient stress, 
self-esteem, and hopelessness.  The complexity of this disease with its biological (pain), genetic, 
and psychosocial components requires holistic management that is tailored to the individual. 
Problem Statement 
Biological, psychological, social, religious/spiritual, and genetic health determinants 
contribute significantly to quality of life for persons with SCD.  Evaluating the positive and 
negative impact of these determinants affords researchers opportunities to identify and design 
interventions to improve health outcomes in persons with SCD (Braverman, Egerter & 
Mockenhaupt, 2011; Marmot & Wilkinson, 2011). 
Gaps in Literature 
As discussed in detail in the integrative review (Chapter 2 of this compendium), much 
prior research has addressed pain in persons with SCD; however, research is scarce on pain 
instruments that include religiosity and spirituality measures (Adegbola et al., 2011; Cooper-Effa 
et al., 2001; Taylor, Stotts, Humphreys, Treadwell, & Miaskowski, 2013).  In the study by 
Adegbola et al. persons with SCD reported that numeric pain scales were inadequate at 
communicating pain needs; participants also reported that faith helped them to manage pain and 
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hoped for an assessment that was comprehensive in conveying their pain experience (2012).  
Thus, inclusion of biopsychosocial-religiosity/spirituality dimensions to instruments used to 
measure the pain of persons with SCD may provide greater knowledge of the pain experience. 
As discussed in the accompanying literature review (Chapter 3 of the compendium), few 
studies have explored the utilization of genetic testing of persons with SCD to prescribe 
medications.  Genetic testing may result in the selection of pain-relieving agents that are safer, 
more efficacious, and individually tailored for a lifetime of chronic and acute pain management. 
The secondary analysis (Chapter 4 of the compendium), examined data to identify 
whether the quality of life of respondents with SCD was statistically significantly associated with 
psychosocial health, specifically depressive symptoms, coping, social support, and self-efficacy.  
Such findings could be foundational and guide future research directed in the development of 
evidence-based psychosocial guidelines. 
Design and Method 
The first manuscript, an integrative review, analyzed quantitative studies of pain 
instruments using a biopsychosocial (BPS) framework in accordance with the National Pain 
Strategy (USDHHS, 2015).  The analysis examined religiosity and spirituality (R/S) measures to 
determine whether the inclusion of R/S to existing or new pain instruments might be an 
appropriate additional measure to improve cultural competence, comprehensive care, and self-
care management for persons with SCD.  The second manuscript, a literature review, explored 
the current science of personalized or precision medicine for sickle cell patients with refractory 
pain during vaso-occlusive episodes (VOEs) to determine if those patients might benefit from 
genetic/genomic testing.  The review reiterated the importance of nurses having a working 
knowledge of genomics and pharmacogenomics to support safer practice and to enhance patient 
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and family teaching and advocacy through the use of genetic testing that can assists providers in 
personalizing treatment for patients with sickle cell disease.  The final manuscript, a secondary 
analysis of data from 179 study participants with SCD from two southeastern U.S. clinics, 
examined associations among quality of life, depressive symptoms, self-efficacy, social support, 
and coping.  Linear regression analyses were used to examine the associations among the 
variables.  By evaluating the associations among the psychosocial dimensions in this 
compendium, the secondary analysis lays the groundwork for future studies to explore best 
practices for humanistic SCD care, thus helping to address a significant research gap.  Currently, 
no evidence-based practice guidelines exist for psychosocial health needs in persons with SCD, 
although studies have suggested that the psychiatric mental health needs of this population are 
greater than the national average. 
Theoretical Frameworks 
Each manuscript has a distinct theoretical framework. Engel’s (1977) biopsychosocial 
(BPS) model of patient care provides for the conceptualization of a full range of human 
experience in health and disease in the integrative review.  This model integrates biological, 
psychological, and social dimensions.  Additionally, informed by the findings, the investigator 
recommended religiosity and spirituality assessments be included to assess the pain experience 
of persons with SCD more holistically.  In the literature review, the author used Rogers’s 
Diffusion of Innovation model to posit that when stakeholders communicate consensus about an 
innovation, adoption of the innovation will likely occur, particularly when additional support for 
the innovation exists within the organization (Horner, Abel, Taylor, & Sands, 2015; Rogers, 
2003).  The Rogers model is important because it has a record of success in improving 
interpersonal communications among stakeholders, often resulting in the adoption of practice 
8 
 
change.  The Self-Care Management for Sickle Cell Disease (SCMSCD) model (Jenerette, 2004; 
Jenerette & Murdaugh, 2008) was the theoretical framework of Jenerette’s original dissertation 
research study.  In the secondary data analysis, the SCMSCD model was valuable for the 
examination of associations among vulnerability factors, self-care management resources, and 
health outcomes. 
The combination of validated existing pain scales with validated measures of religiosity, 
spirituality, and psychosocial factors can guide future research to assess persons with SCD 
holistically.  Although personalized (or precision) medicine that uses genetic testing is in its 
infancy, patients and providers are using genetic testing to ensure safe and specific therapies.  
The SCMSCD model can be used to guide nursing interventions for this vulnerable population. 
Grounded in the latest understanding of interdisciplinary team care for patients and 
families, this compendium of studies relies upon holistic concepts and available scientific and 
humanistic understanding to address the multidimensional needs of persons with SCD.  Until 
genetic interventions are introduced that correct the genetic code mutation responsible for 
triggering the sickling of RBCs, (Chandrakasan & Malik, 2014; Hoban et al., 2015; Perumbeti & 
Malik, 2010; Romero, 2013) holistic health management is a worthy recourse to address pain and 
disease-related complications in this patient population (Koshy & Dorn, 1996; Smy, 2004; 
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Table 1. Manuscript Comparisons 
 Manuscript 1 Manuscript 2 Manuscript 3 
Title Integrative Review of 
Pain Instruments for 
Sickle Cell Patients in 
the Emergency Setting 
The Application of 
Genomic Testing for Pain 
Management in Sickle 
Cell Disease 
Associations between 
Psychosocial Measures in 
a Sample of Adults with 
Sickle Cell Disease 
Topics Pain measures 
biopsychosocial 
Genomic testing QoL, depression, 
psychosocial influences 
Method Integrative review Literature review Secondary data analysis 
Population 
issues 
Persons with sickle 
cell holistic pain 
management 
Persons with sickle cell 
holistic pain management 




Instruments Patient assessment 
tools re: pain 
Patient assessment tools 
re: genomics 
Patient assessment tools re: 
psychosocial attributes 
Findings Recommandations for 
practice and evaluate 
patient outcomes 
Recommendations for 
practice and evaluate 
patient outcomes 
Recommendations for 
practice and evaluate 
patient outcomes 
Innovation Proposing the addition 
of Religiosity/ 
Spirituality 
dimensions to existing 
pain instruments 
Proposing the addition of 
Genomic testing, 
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Objectives: This integrative review analyzes pain instruments using a biopsychosocial (BPS) 
framework in accordance with the National Pain Strategy.  Religiosity and spirituality (R/S) 
measures were analyzed to assess whether the instruments include R/S and how this aligns with 
the BPS framework. An instrument inclusive of BPS-R/S measures may contribute to 
comprehensive pain assessment for persons with sickle cell disease SCD). 
Methods: A review of the literature was conducted following a search in ProQuest Nursing and 
Allied Health Source, National Library of Medicine (PubMed), Cumulative Index for Nursing 
and Allied Health Literature (CINAHL), and PsycINFO.  The BPS model modified with R/S 
dimensions provided the framework to evaluate pain instruments that can be used to measure 
pain in persons with SCD in emergency departments (ED).  Inclusion criteria were 
unidimensional and multidimensional pain instruments, as well as scholarly peer-reviewed 
quantitative studies of human subjects published in English between 2003 and 2013. 
 Results: Ten instruments were examined for their biometrics and biological, psychological, 
social, religious, and spiritual (BPS-R/S) dimensions.  The Wong-Baker Faces Scale 
(unidimensional) and the PAINReportIt (multidimensional) instruments demonstrated the 
strongest validity for use with persons with SCD in the ED during acute pain crises.  None of the 
ten instruments included the dimensions of religiosity and spirituality. 
Conclusion: The use of pain instruments containing BPS components may facilitate meaningful 
treatment planning.  The use of multidimensional instruments with the addition of R/S 
instruments is in accord with self-care strategies used by persons with SCD.  




Integrative Review of Pain Instruments for Sickle Cell Patients in the Emergency Setting 
Pain is the hallmark symptom of patients with sickle cell disease (SCD) (Ballas et al, 
2010; Jenerette & Brewer, 2010; U.S. Department of Health and Human Services [USDHHS], 
2014).  Rapid assessment and initiation of parenteral opioid therapy is a necessity for the 
management of pain associated with vaso-occlusive crisis (VOC) in the emergency department 
(ED) (Ender et al., 2014). Pain control for the patient with sickle cell has been reported to be 
inadequate in the ED resulting in patient dissatisfaction, return ED visits, hospitalizations, and 
fatalities (Ender et al., 2014; Solomon, 2010). 
The purpose of this review is to investigate pain instruments that can be used in ED 
settings for persons with SCD during vaso-occlusive crises (VOC).  The biopsychosocial (BPS) 
framework recommended by the National Pain Strategy guided the evaluative process.  In 
addition to the biological, psychological, and social, dimensions, religiosity and spirituality (R/S) 
dimensions were included in order to determine the existence and efficacy of comprehensive 
pain instrument(s). 
Background 
Sickle cell disease (SCD) is a recessive, genetic, hematologic disorder affecting 70,000 - 
100,000 Americans (USDHHS, 2014).  Several sickle cell genotypes result in variations in 
disease characteristics.  Persons with homozygous hemoglobin SS (Hb SS) and hemoglobin Sβ 
thalassemia (Hb Sβ) genotypes and those with lower levels of fetal hemoglobin (HbF) 
experience severe complications.  The etiology of SCD and abnormal ‘sickle’-shaped red blood 
cells (RBC) is due to the amino acid substitution of glutamic acid by valine, located in the beta 




Individuals with SCD experience various complications including vaso-occlusive crises 
(VOC), also known as vaso-occlusive episodes (VOE) or sickle cell crises (SCC) (Frei-Jones, 
Baxter, Rogers, & Buchanan, 2008). During VOC, misshaped and inflexible RBCs obstruct the 
flow of oxygenated blood to cells, tissues, and organs resulting in inflammation, tissue damage, 
and excruciating pain (Centers for Disease Control and Prevention (CDC), 2011; Smith & 
Scherer, 2010; U.S. Department of Health and Human Services (USDHHS), 2011a; U.S. 
Department of Health and Human Services (USDHHS), 2014). It is difficult to assess the 
physiologic impact of VOC and the accompanying pain.  Pain is defined as “an unpleasant 
sensory and emotional experience associated with actual or potential tissue damage, or described 
in terms of such damage” (Merskey, 1994, p.S69).  Pain also has been described as “whatever 
the experiencing person says it is, existing whenever the experiencing person says it does” 
(McCaffery,1968, p.95). 
Pain measurement and control are priority elements of care for the person in VOC. For 
the purposes of this paper, pain measurement is either the use of unidimensional instruments to 
assess pain intensity, generally using a self-reported rating scale, or the use of multidimensional 
instruments to rate pain intensity, describe pain location, quality, duration, and pattern, and in 
some instances, evaluate the patient’s behavioral coping strategies for pain. 
This integrative review is an analysis of the scientific literature reporting reliability, 
validity, and feasibility of instruments used to measure the pain experience of persons with sickle 
cell disease.  It contains information pertaining to the state of the science, identifies theoretical 
concepts, and recommends instruments useful for clinical practice in the emergency department 
(ED) setting (Whittemore & Knafl, 2005). A biological, psychological, social, religious, and 
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spiritual (BPS-R/S) theoretical approach was used to evaluate whether current pain instruments 
are useful for patients with SCD as well as to recommend future research. 
Pain management associated with VOC and several other serious complications requires 
emergency treatment (Tanabe et al., 2010), which includes management of pain, dehydration, 
infection, and other acute issues.  Treatment includes, but is not limited to, opioid agents 
(Dampier et al., 2013).  Despite established treatment regimens and algorithms, patients with 
SCD report experiencing inadequate pain control and care during VOC in their emergency 
experiences (Dorsey, Phillips, & Williams, 2001; Lattimer et al., 2010).  The pain associated 
with a VOC can last from hours to weeks (Human Genome, 2005), and these ischemic episodes 
have resulted in disability and death (Ghatpande et al., 2008).  The frequency of VOC varies, and 
a range of pathophysiologic phenomena may occur throughout the lifespan of persons with SCD 
(Lettre et al., 2008; Tanabe et al., 2010).  Some patients may experience as few as one crisis per 
year, and some may have as many as 25 (Jenerette, 2004); however, Brousseau and colleagues 
defined 3 or more hospitalizations for VOC in a 3-year period as severe disease (Brousseau, 
McCarver, Drendel, Divakaran, & Panepinto, 2007). 
Nurses have an integral role in conducting best practices associated with ED care and 
pain management during patient assessment, education, medication administration, and in 
determining the efficacy of doses administered.  Nursing leadership and advocacy in the ED 
management of the patient with SCD is crucial in promoting culturally competent care and 
facilitating positive health outcomes, especially related to assessment and control of pain 
(Wilson & Nelson, 2015).  This review (a) explores multiple pain scales used to evaluate acute 
and chronic pain and (b) identifies instruments used in studies to measure pain in patients with 
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SCD, and (c) assesses the biometrics and the biological, psychological, social, religious, and 
spiritual (BPS-R/S) dimensions of those pain scales. 
Theoretical Framework 
(Borrell-Carrió, Suchman, & Epstein, 2004; Engel, 1980; Gatchel, Peng, Peters, Fuchs, & 
Turk, 2007; Roth, Geisser, & Williams, 2012; Smith et al., 2005).  The biopsychosocial model is 
highly referenced by the National Pain Strategy (NPS) and others as a means of assessing, 
planning, implementing, and evaluating pain care in a manner that is specific to the needs of the 
person in pain (USDDHS, 2015).  Taylor, Stotts, Humphreys, Treadwell, and Miaskowski (2013) 
recognized the significance of integrating religiosity and spirituality into the BPS model.  
Research that measures these additional areas and their associations with pain and pain control 
may be useful in developing pain management strategies.  Taylor et al. and other researchers 
have validated using a more holistic perspective to enhance provider/researcher understanding 
beyond the disease concept, into the additional areas of life control, social support, coping, self-
management, and transcending disease (Adegbola, 2011; Cooper-Effa, Blount, Kaslow, 
Rothenberg & Eckman, 2001; Cotton et al., 2009; Harrison et al., 2005; Tanyi, 2002; &Yoon & 
Black, 2006). 
This review evaluates the evidence of instruments using the BPS framework integrated 
with the concepts of religiosity/spirituality (Table 1).  Religiosity/Spirituality will be connoted as 
‘R/S’ for the remainder of this manuscript.  Religiosity embodies belief in a higher power or God 
and may include participating in organized spiritual practices such as prayer groups or church 
attendance (Tanyi, 2002).  Spirituality will be conceptually defined as a personal experience that 
is beyond the corporeal, It has been described as a “synthesis of personal beliefs about the 
essence of being” (Adegbola, 2011) that “involves humans’ search for meaning in life… 
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acceptance of hardship and mortality, a heightened sense of physical and emotional well-being, 
and the ability to transcend beyond the infirmities of existence” (Tanyi, 2002).  Spirituality is 
operationally defined as any instrument containing items pertaining to faith or beliefs, the value 
or importance of faith or beliefs, the use of faith or beliefs as a means of coping with biological, 
psychological or social stressors, identifying participation in a community of faith or responses 
to action steps in support of faith or beliefs (Draper, 2012).  Although specific definitions of 
religiosity/spirituality (R/S) differ, there are similarities in patient/participant interpretation of 
these terms.  In one sample of adolescents, 11-19 years of age, 46% believed that R/S meant the 
same thing, (Cotton et al., 2009). 
While there has been significant debate about spiritual care in the public healthcare 
environment (Draper, 2012), academic and theoretical debates have little to do with the actual 
beliefs of patients and research participants.  General screenings of persons with SCD to 
determine their religious and spiritual status are valuable from the natural systems perspective 
and are inclusive of patients’ needs (Draper, 2012; Engel, 1977).  The current study is grounded 
in the belief that using a BPS-R/S theoretical approach will result in improvements to 
comprehensive and culturally competent pain management because prior studies of participants 
with SCD have identified that religiosity and spirituality are important to them (Adegbola, 2011; 
Cotton et al., 2009; Harrison et al., 2005; Jenerette & Lauderdale, 2008; Taylor, Stotts, 
Humphreys, Treadwell, & Miaskowski, 2013). 
Methods 
Literature Search Methods:  Following consultation with a research librarian, a search of 
quantitative literature was conducted for instruments measuring pain in individuals with SCD in 
the following databases: ProQuest Nursing and Allied Health Source, National Library of 
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Medicine (PubMed), the Cumulative Index for Nursing and Allied Health Literature (CINAHL), 
and PsycInfo.  The following terms were used in ProQuest: “pain,” “sickle cell,” and 
“instruments.”  The search yielded 346 articles.  Limiters included quantitative, scholarly, peer-
reviewed, human subjects, all age groups, document types identified as evidence-based 
healthcare, and literature reviews in the English language written between 2003 and 2013.  One-
hundred and three studies remained and were hand sorted for specific instruments used to 
measure pain in patients with SCD, with preference for patient status of VOC.  Four studies met 
the inclusion criteria after reviewing and sorting the ProQuest database search. 
In the initial PubMed search, the key terms “pain,” “sickle cell,” and “instruments” 
yielded four studies.  Upon review, the first two were excluded for being out of the selected 
period (one was published in 1993 and another in 1996), and the third and fourth studies were 
excluded for not addressing pain specific instruments used in the SCD population.  A second 
search of PubMed using “pain,” “sickle cell,” and “validity” resulted in 19 studies.  After a 
review of the abstracts and other subsections, 3 studies were retained because they met the 
criteria and also provided information about the validity of pain scale instruments. 
In the CINAHL database, no studies were found using the key terms “pain,” “sickle cell,” 
and “validity”; “pain,” “sickle cell,” and “measurement”; or “pain,” “sickle cell,” and 
“instruments.”  A broadened search using the terms “pain” and “sickle cell” resulted in 254 
articles.  Limits were set to include the previously mentioned time frame, the source type from 
academic journals, either gender, all ages, and the subheadings pain and emergency care.  After 
studies outside the U.S. were excluded, twelve articles remained.  A hand search involving the 
review of abstracts, methods, samples, and results led to the retention of 3 studies. 
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A PsycINFO search using the thesaurus key words “Test Validity,” “Sickle Cell,” and 
“Pain” yielded four results; of these, two were qualitative, one was a duplicate previously 
identified through a search in ProQuest, and one did not meet the inclusion criteria.  No 
additional studies were retained from PsycINFO.  See Figure 1 for an overview of search 
methods. 
Methods for Assessment of Instruments:  The investigators evaluated the validity, reliability, 
and feasibility of pain instruments from ten SCD studies.  The Oxford Centre for Evidence Based 
Medicine (OCEBM) guidelines were used to evaluate and rank the evidence in the studies using 
a Likert-like scale of 1-5; the smaller number indicates higher level study evidence (Howick et 
al., 2011). 
The studies were examined for theoretical approach, and the instruments were examined 
for associations with BPS-R/S dimensions (Dampier et al., 2013; Edwards, et al., 2006; 
Frei-Jones et al., 2008; Luffy & Grove, 2003; McClellan et al., 2009; Myrvik et al., 2013; Smith 
et al., 2005; Wilkie et al., 2010; Zempsky et al., 2013a & Zempsky et al., 2013b).  The BPS 
dimensions were operationalized as a pain instrument measuring the biological, psychological, 
and social attributes of pain including intensity levels, descriptive assessment of patient burden, 
affective of emotional measures, adaptation and functional status (Benjamin, 2008). 
Results 
The authors identified that the 10 studies all contained higher-level evidence with a rating 
of 2 on the 5-point scale.  Ten pain instruments were evaluated within the 10 studies included in 
this review and are listed in Table 1. 
Of the 10 pain instruments used with patients with SCD, the most frequently used 
instrument was the visual analog scale (VAS) (Dampier et al, 2013; Edwards, et al., 2006; Luffy 
& Grove, 2003; McClellan et al., 2009 & Myrvik et al., 2013).  The Wong-Baker Faces Scale 
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(WBFS) was the preferred unidimensional instrument for African American preschool-aged and 
older children with SCD (Luffy & Grove, 2003; McClellan et al., 2009). 
Table 1 also lists the instruments by unidimensional and multidimensional status.  Four 
studies used 1 or more unidimensional instruments (Frei-Jones, et al., 2008; Luffy & Grove, 
2003; Myrvik et al., 2013; Zempsky et al., 2013b), and 5 studies used unidimensional in 
conjunction with multidimensional instruments (Dampier et al, 2013; Edwards, et al., 2006; 
McClellan et al., 2009; Smith et al., 2005; Wilkie et al., 2010). 
Of the 10 studies reviewed, only two described using a theoretical framework.  Luffy & 
Grove (2003) used Leininger’s Theory of Nursing Cultural Care Diversity and Universality to 
communicate the importance of using instruments that are valid, reliable, and culturally 
competent when examining non-white children during sickle cell clinic visits.  Smith et al. 
(2005) used a combination of research models:  Andersen’s health care utilization, Engle’s 
biopsychosocial (BPS) theory, and the Health Belief Model (HBM) to develop a conceptual 
framework of pain and response to pain in SCD.  Their multidimensional approach using diary 
entries solicited descriptive reflections of coping strategies; this exercise resulted in a need for 
less health care support.  The design of the diary contains very useful inquiries for health 
reflection, but not for the emergent needs of persons in acute pain. Table 1 lists the dimensions 
of the BPS in each of the instruments.  None of the pain instruments addressed 
religiosity/spirituality. 
As indicated in Table 1, all of the multidimensional instruments evaluated the biological 
and psychological dimensions, and some included social influences of the patient’s pain 
experience (Dampier et al, 2013; Edwards, et al., 2006; McClellan et al., 2009; Smith et al., 
2005; Wilkie et al., 2010; Zempsky et al., 2013a). 
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The VAS has a demonstrated record of success (Salo et al., 2003), and the WBFS was 
preferred by youths.  For each unidimensional instrument, key factors regarding their clinical use 
include: the respondent must understand the instrument being administered, consistent use by 
knowledgeable providers is essential (Berry et al., 2001; Herr & Garand, 2001), and the provider 
needs to be responsive to the intensity rating stated by the patient (Schiavenato & Alvarez, 
2013). 
The multidimensional instruments used in the clinical studies assessed in this review can 
guide the development of interventional strategies associated with the pain experience.  Each of 
the instruments has components that provide a greater understanding of pain burden and 
experience. 
Samples 
Two studies evaluated the adult (18 years or older) population (Edwards et al., 2006; 
Wilkie et al., 2010), and the remainder were a mix of ages primarily consisting of children and 
young adults 2-21 (Table 2). 
The samples in the studies identified the racial and ethnic backgrounds of those with SCD 
as African American/Blacks: 76% - 93.8%, Caucasian/Whites: 1.4% - 8%, Hispanics: 2.8% - 
12%, and those who identified as being of more than 1 race: 2.1% - 12% (CDC, 2011; Wilkie et 
al., 2010; Zempsky et al., 2013a & Zempsky et al., 2013b).  Some of the studies did not identify 
the racial demographic of the participants (Dampier et al., 2013; Edwards, et al., 2006; Frei-
Jones, et al., 2008; McClellan et al., 2009; Myrvik et al., 2013; Smith et al., 2005). 
There were no exclusions based upon sickle cell genotype in the selected studies.  Six 
studies had no age exclusion (Dampier et al., 2013; Frei-Jones et al., 2008; Luffy & Grove, 2003; 
Myrvik et al., 2013; Smith et al., 2005;  Zempsky et al., 2013b). 
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Reliability and Validity 
In many studies, the pain instruments were well established and reports of their reliability 
and validity were based upon prior research. Standard reliability analyses were reported in 6 of 
the 10 studies using Pearson’s r scores, Cronbach’s alpha, test-retest, or inter-rater procedures.  
Validity analyses were reported in 7 of the 10 studies.  Content, convergent, construct, and 
concurrent validities were identified.  Reliability and validity in the unidimensional instruments 
were r = 0.54 – 0.72 p-value <.001 and content validity per Kendall’s coefficients 0.726, p<0.01 
for the African American Oucher Scale (AAOS);  r = 0.63 – 0.94, p < 0.001 and concurrent 
validity =  X2 = 1.21, df = 5 for the WBFS;  r = 0.87 and construct validity r =  0.44, r = 0.28, r= 
0.44, p< 0.001 between parent and child, nurse and child , nurse and parent for the VAS (Luffy 
& Grove, 2003).  No reliability or validity data were given for the numeric rating scale (NRS) 
however, Zempsky et al., reported established validity in other cited work (2013) (Table 2).  
Reliability and validity statistics in the multidimensional instruments were not reported in 
Dampier et al. for the Brief Pain Inventory (BPI).  The daily pain diary study did not have 
reliability and validity data; however, face validity was discussed and Gil, Carson, & Sedway, 
2000, reported that pain diaries have been used with success in this population (Smith et al., 
2005).  McClellan et al. reported criterion validity r = 0.49 p <0.01 and a reliability range of 0.68 
– 0.72 for the observable scale of behavioral distress (mOBSD).  Wilkie et al., referenced 
validity found in another study (Jha et al., 2010) in a sample of persons with sickle cell and a 
30-year research use to establish validity and Cronbach's alpha for internal consistency reliability 
of .63, .77, and .75 in the barrier portion of the computerized McGill Pain Questionnaire entitled 
PAINReportIt (2010).  Zempsky et al, 2013a reported construct validity between group t= -5.12, 




The time required to administer an instrument is significant when assessing patients in 
sickle cell crisis.  Many of the unidimensional scales and the pain intensity sections of the 
multidimensional scales (VAS, AAOS, NRS, and WBFS) contain self-report tools that require 
minimal time and minimal or no cost, with low participant burden (Table 2).  Unidimensional 
instruments are highly regarded for their efficient assessment of acute pain intensity at the time 
of a VOC.  The time required to complete a unidimensional instrument was typically 1 minute. 
Discussion 
The purpose of the review and the theoretical framework served as the guidelines for 
instrument selection.  When choosing a unidimensional instrument to measure pain rating in the 
clinical setting, providers must consider the age of the person being evaluated.  In selecting the 
best unidimensional instrument, reliability, validity and feasibility should be considered in 
addition to the preferences of the sample (Luffy & Grove, 2003). 
Although the studies had reliability, validity, and feasibility, the decade in which they 
were published was characterized by patients reporting their pain needs were not met, and 
providers reporting frustration in their caregiver role with persons with SCD (Lattimer et al, 
2010; Mathias & McCavitt, 2015; Tanabe et al., 2010).  Many studies of persons with SCD 
report stigmatization and disparate care (Haywood et al., 2009; Haywood et al., 2014; Jenerette, 
2004; Jenerette & Brewer, 2010; Jenerette, Funk, & Murdaugh, 2005).  Addressing the issue of 
stigmatization among all providers and suboptimal care in the ED (Schiavenato & Alvarez, 
2013) is pivotal to making the changes needed to improve pain care in the ED setting.  Nurses 
are essential in managing the existing patients’ perceptions of stigma through the utilization of 
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patient advocacy, clinical expertise, and the nursing process in pain management (Wilson & 
Nelson, 2015). 
Unidimensional scales are brief, thus useful in the ED, but they have limitations; they are 
self-report instruments and offer information pertaining to pain intensity only.  Research has 
identified that providers underrate self-reported data and question the value of unidimensional 
instruments in measuring the extreme pain of VOC (Schiavenato & Alvarez, 2013).  On these 
scales, a rating of 0 means the pain is absent;  5 or 10, depending on the scale, indicates pain is at 
its worst (Luffy & Grove, 2003), yet perceptions of pain intensity can vary greatly among patient 
populations.  The visual analog scale (VAS) a unidimensional instrument, is well established in 
the population with sickle cell, but has poorer efficacy in young children (Luffy & Grove, 2003) 
as well as persons with learning deficits or cognitive impairment (Berry et al., 2001; Herr & 
Garand, 2001). 
While multidimensional instruments are meritorious, respondent burden must be 
considered when administering instruments from this group in the ED environment.  
Multidimensional instruments contain specific items used to obtain information pertaining to the 
multiple characteristics of the patients’ pain.  These instruments allow more details of the unique 
features of the patients’ pain experience (Dampier et al., 2013; Wilkie et al., 2011; Zempsky et 
al., 2013a).  Time to completion and respondent burden during an acute pain episode are the 
main limitations.  The SCPBI-Y, a multidimensional instrument, has a 1-minute completion time 
but it lacks necessary ED screening information, such as a pain scale, since it measures pain 
burden. 
Evidence-based strategies used with a BPS-R/S approach may contribute to the 
assessment of persons with SCD by including additional holistic dimensions that patients may 
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appreciate.  Research demonstrates that many persons with SCD value spirituality and religiosity 
(Adegbola, 2011).  Research that creates R/S assessment items or uses existing instruments that 
measure these concepts also can be designed to address the cultural and traditional values of 
some persons with SCD and, thus, may result in a more culturally competent and comprehensive 
assessment.  This information will enhance provider and researcher knowledge and should be 
considered for assessment and for care planning (Taylor et al., 2013).  Provider support of 
spirituality and religiosity practices is linked to patient perceptions of decreasing (or decreased) 
pain, the hallmark symptom of SCD (Cooper-Effa et al., 2001; Taylor et al., 2013). 
Several instruments have been used in healthcare research to measure spirituality.  
Adegbola (2011) and Cotton et al. (2009) used the Functional Assessment of Chronic Illness 
Therapy-Spiritual (FACIT-Sp), a 12-item instrument to measure spirituality in persons with 
SCD.  Draper identified nine “General Spirituality” and seven “Spiritual Wellbeing” instruments 
in an integrative review of spiritual assessment (2012, p.973).  For organizations introducing 
spiritual assessment to their clinical environment, the researcher suggested the Faith and Belief, 
Importance, Community, Address in Care or Action (FICA) model.  FICA is a 4-step model that 
is considered general because it is not specific to a particular religious or spiritual group, and it is 
easy to administer (Draper, 2012). 
Asking participants to identify their ethnic and racial identities is valuable because this 
cannot be assumed by appearance.  Health officials are attempting to gather accurate 
demographic information about persons with SCD (CDC, 2014; Taylor et al., 2013).  While the 
majority of persons with SCD in the United States are African American (Black), SCD is present 
in other racial and ethnic minority groups.  These groups include people who are Mediterranean, 
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Arabian, Indian (East), South American, Central American and Caribbean or their descendants 
(Piel et al., 2010; USDHHS, 2011b). 
Herr & Garand identified age, culture, ethnicity, gender, spiritual and family as 
influential factors to consider when assessing pain (2001).  It is also essential to evaluate the 
mental status and for other barriers to understanding.  Using an interdisciplinary approach to pain 
management may be helpful in addressing the factors that impede understanding and successful 
outcomes. 
Younger participants and those experiencing communication barriers typically have had 
difficulty with the linear unidimensional scales (VAS and NRS) and have fared better with faces 
scales, e.g. the AAOS and WBFS scales (Luffy & Grove, 2003; Flaherty, 2012).  However, 
facial expressions are culturally determined, and limits exist regarding the universality of the 
faces instrument.  Children have preferred the WBFS. Yet the WBFS can be used to assess 
persons of any age unless the individual is visually or cognitively impaired.  The faces scale also 
contains a 0 - 5 numeric rating under each pictured face. 
When choosing a multidimensional instrument, the following factors are significant:  the 
reliability, validity, ED feasibility, BPS framework, the age of the participant, and successful use 
in persons with SCD.  The mean ED wait time is 46.5 minutes to 58.1 minutes (Hing & Bhuiya, 
2012).  This timeframe provides an adequate opportunity for the administration of most 
multidimensional instruments.  The PAINReportIt instrument was consistent with the 
aforementioned criteria for use in the ED during acute pain crises because it has a history of 
success in research with persons with SCD, it addresses 2 (biological and psychological) of the 5 
pain dimensions (BPS-R/S), and it includes integral findings (pain location, rating, and 
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biological and psychological factors) needed to manage acute pain in the ED (Wilkie et al., 
2010). 
Based on this in-depth review of the research on the 10 identified instruments, the 
investigators determined that the PAINReportIt, a multidimensional instrument, has an average 
completion time of 21.4 minutes, making it viable for ED use.  Descriptive analysis, Pearson’s 
correlations, and Students t tests were used to examine the associations among the variables.  
Cronbach’s α for internal consistency reliability ranged from .63 - .77 in the Barrier 
Questionnaire component of the instrument.  Correlations among pain rating indices (PRI) were 
in unison with similar studies and contributed to the validity of the Wilkie et al. study (2010).  
The first McGill Pain Questionnaire (MPQ) was published in 1975 (Melzack, 1983) and has a 
30-40-year history of being used to measure pain.  The PAINReportIt software is a computerized 
version of the MPQ, a multidimensional instrument developed by Nursing Consult LLC.  
Researchers followed a structured protocol in the delivery of the pain assessment instrument and 
were available to respondents for questions (Wilkie et al., 2010).  This instrument does not 
contain R/S components.  An additional instrument with R/S variables may provide an 
opportunity for testing the utility of R/S factors. 
Limitations 
The results of the search of quantitative literature for instruments measuring pain in 
individuals with SCD during VOC were limited.  The 10 pain instruments evaluated the pain of 
patients with SCD during VOC and non-VOC events.  The search was also limited to studies 





Patients typically expect comprehensive assessment of their current health status, clear 
communication, and prompt pain management (Lattimer et al., 2010).  Providers and researchers 
value instruments that facilitate detailed and systematic guidance of the health care needs of 
persons with SCD.  The acute pain in VOC is not merely a physiological phenomenon; it is 
associated with chronic disease progression, as well as biopsychosocial and spiritual factors.  
Utilizing multidimensional instruments broadens researcher and provider knowledge about the 
quantitative and qualitative indices of the pain experience of patients with SCD. 
The pain experience is difficult to assess because pain is unique to the person.  As a basis 
for developing optimal planning in the care environment, it is necessary to determine the 
validity, reliability, and feasibility of instruments used to measure pain.  The use of well-
established and comprehensive instruments to measure patient needs and to establish an 
algorithm for pain management to decrease pain and tissue damage during VOC will improve 
provider effectiveness and decision-making with patients and, thus, optimize health management 
(Adegbola et al., 2012; Tanabe et al., 2010; USDHHS, 2014).  The results from this review can 
help provide a foundation to assess and develop interventions associated with a natural systems 
approach to illness management, including research on new protocols for persons with sickle cell 
disease (SCD).  Testing the use of the PAINReportIt instrument and FICA 4-step model may 
provide data useful in improving outcomes in persons with SCD. 
Conclusion  
The agendas of the National Pain Strategy (NPS) validate the importance of the 
biopsychosocial (BPS) approach to pain care with numerous references to the model (USDHHS, 
2015).  The addition of the religious and spiritual dimensions to the framework extends the 
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model and serves as the foundation and guide for this review.  Using a BPS-R/S approach 
encourages primary providers to engage in interdisciplinary collaboration with psychology, 
social work, and chaplaincy team members; to support culturally meaningful practices; and to 
promote comprehensive pain care.  Future research and collaboration with an interdisciplinary 
clinical and pastoral team are recommended to pilot test the conclusions in this review and to 
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627 records identified through 
database search; ProQuest=346, 
PubMed 4 + 19=23; CINAHL= 
254; PsycINFO=4 
1 duplicate removed 
Narrowed by exclusion 
criteria: 118 studies 
remaining 
10 studies remaining 
508 studies removed with limits: 
specified to retain studies w/ 




108 studies excluded that did 
not meet inclusion criteria: 
quantitative, pain, SCD, 
instruments, and 
measurements 




Table 1 – The biological, psychological, and sociological (BPS) dimensions of pain 
instruments 
Instrument Biological Psychological Social 
       
Unidimensional       
African-American oucher scale (AAOS) X     
Numeric rating scale (NRS) X     
Visual analog scale (VAS) X     
Wong-Baker faces scale (WBFS) X     
Multidimensional       
Brief pain inventory (BPI) X X X 
Sickle cell pain diary (SCPD) X X X 
Observable scale of behavioral distress 
 (mOSBD) 
X X   
PAINReportIt  (cMPQ = computerized MPQ) X X      
Short form-McGill pain questionnaire (SF-MPQ) X X   
Sickle cell disease pain burden interview-youth 
(SCPBI-Y) 
X X X  














Validity Reliability Feasibility of using 
Instrument 



















100 African American 
children w/SCD;  
51% males 
49% females; 
Age 3-18 years 
Mean age 8.52 years 
 
 Divided into age groups 
based on Piaget cognitive 




reporting pain pictures 
of child 
 
Intensity rating tool 0 - 
100 (increments of 10) 
by identifying with 1 
of 6 pictures that 
demonstrate no pain to 
worst pain   
Numeric ratings for 
children who can count 





0.7256, p < 0.01 from 






coefficients 0.732 to 
0.981 and 0.003 to 




Interrater reliability  of 
90% achieved 
 
Reported r = 0.54 to 
0.72, p < 0.001 from 
Belter, McIntosh, Finch, 
and Saylor, 1988 
 
AAOS -6- item scale, 
simply and quickly 
administered  
2 Brief Pain Inventory  
short form 
 (BPI- F), 
 
Dampier et al., 2013 
 
 
No e reported 38 participants (4 
withdrew) with all 
genotypes of SCD 
 
> 10 years of age w/acute 





i tr t; items using 
yes or o, 
identification of pain 
sites and a rating scale 
 
None r ported  
construct validity 
found in  Atkinson et 
al., 2011 Correlation 
coefficients p< 0.05 
Correlation of the SF-
36 Mental Health scale 
is excellent with the 
variou  su mary 




12- item (Spearman’s 
ρ=-0.61). [Raichle et 
al. 2006] 
None reported 
Cronbach’s α reliability 
ranges: 
 0.77-0.91 found in 
Atkinson et al., 2011 
Internal consistency of 
the BPI is excellent for 
the 7-item scale 
(Cronbach’s α=0.92), 
the 10-item scale 
(Cronbach’s α=0.95) 
and the 12-item scale 
(Cronbach’s α=0.96). 
[Raichle et al. 2006] 
No cost for use of BPI 
instrume t unless used 
co mercially or for funded 
research;  
BPI-SF: self-administered 
completed  in 10-15 
minutes 
 
Daily pain diary 
 





Model of Pain 
and Response 
to Pain in SCD 
& Health 
Belief Model 
300 eligible participants 
with SCD   
Age 16 years or older  
Living in VA 
Inclusion: patients able to 
communicate by phone and 
complete the diary  
Exclusion: patients with 





participants rate & 
record their pain, 
distress and disability 
on an ordinal scale 




Pain diaries have been 
used with success in 
this population (Gil, 
Carson & Sedway, 
2000) 
No validity data 
reported. 
None reported Pain diaries rely on subject 
to complete and return to 
reviewers; clear guidelines 
about diary submission 
schedules and the 
importance of providing 
support and structure to 
facilitate their 
participation. The design 
has limits to use of this 










Myrvik et al., 2013 
None reported 28 participants 
Age 8-18 years  




Inclusion: any genotype of 
SCD receiving analgesic 
treatment for 
uncomplicated VOC; 
English primary language 





NRS patient identifies 
a number by writing 
down a number 
between 0 and 10 that 
relates to their pain 





Zempsky et al., 2013b None reported 25 participants 











Not reported 4% 





NRS patient identifies 
a number between 0 
and 10 that relates to 
their pain.  
Referenced validity 
from  Bailey et al., 
2010; Von Baeyer et 
al., 2009  
None reported NRS 11-item scale, simply 
and quickly administered 
2 




McClellan et al., 2009 
None reported 48 participants w/ SCD 
receiving venipuncture as 
part of routine health 
maintenance visits 
Ages 2-17 years 
Mean age 9.6 years  
3 age groups: 2-4, 5-9, 
&13-18 years 
24 males 
24 females  
mOSBD:  a 
multidimensional 
instrument;  children 
were videotaped to 
assess presence or 
absence of  11 
behavioral indicators 
of procedural distress, 
used raters to monitor 
video recordings of 
observed  pain 
experiences & 
behavior to determine 
the level of distress 
associated with a 
painful medical 
procedure. The 2 raters 
were trained with 93- 
100% interrater 
agreement 
Criterion validity of 1st 
hypothesis 
r = 0.49 p < 0.01 
 
3 age groups: 
t = (11) = 3.86, p < 
0.01; 
t (12) =1.94, p < 0.05;  
t = (18) = 2.12, p < 
0.05 
Instrument reliability: 
Cronbach’s alpha range 
0.68 to 0.72  
 
Reported as a reliable, 
valid instrument (Jay et 
al 1983). 
 
This scale requires 
extensive training and 
assessment of trained 





PAINReportIt ,  
 
A computerized 









None reported 145 participants with SCD 
Age 18 years or  older 
AA 93.8%, White 1.4%, 
Hispanic 2.8%;  
More than1 race 2.1%  
 
Participants received 
outpatient care at SCD 




measures pain location, 
intensity, quality & 
pattern 
PAINReportIt-Plus-
ABQ software is 
computer extension of 
the McGill Pain 
Questionnaire (MPQ) 
Referenced validity in 
Using PAINReportIt 
instrument in persons 
with SC from Jha et 
al., 2010 
 
Reported 30 year 
research history using 
MPQ to establish its 
validity 
Cronbach’s alpha  for 
internal consistency 
reliability + .63, .77, .75; 
in the Barrier portion of 
the questionnaire. 
Reported 30 year 
research history using 
MPQ to establish its 
reliability. 
Pen-tablet computer 
required; subjects were 
given ‘standardized’ 
practice before beginning; 
Feasibility was measured 
using a computer 
acceptability scale (CAS) 
0-13 ranking 
PAINReportIT total time: 
Mean 21.4 minutes 








A Paper format 
 





67 Adult participants 
Ages 18-70 years  
30 males 
37 females 
Race not identified 
 
Enrolled in Duke 
Comprehensive Sickle Cell 
Center 
SF-MPQ – A 
multidimensional 
instrument; subjects 
rate the current 
intensity of each pain 
adjective by circling: 
none, mild, moderate, 
severe 
None reported  SF-MPQ: None reported 
for current study. 
 
Found test –retest 
reliability per intraclass 
correlations of 0.96, 
0.95, 0.88, & 0.89 in 
sample w/o SCD in 
Grafton, Foster and 
Wright , 2005 
SF-MPQ: no feasibility 
data reported 
2 
The Sickle Cell 




Zempsky et al., 2013a 
 
None reported 62 outpatient English-
speaking participants; 
Ages 7-21years 






11.5 % Hispanic 
during acute pain   
  
 67 inpatient English 
speaking participants 
7-21years 
M = 15.70 
43.3% male; 56.7%  
female;  
89.7% Black  
6.1% Hispanic 
SCPBI-Y- A 7-item 
multidimensional 
Likert- type instrument 
(none = 0, few = 1, 
some = 2, many = 3, 
every = 4 
 
Designed to assess 
impact of pain on 
physical, social 
/community, & 
emotional aspects of 
daily function.  
 
Range 0-28 (0 = no 
pain burden to 28 = 




by a positive 
relationship between 
higher pain burden and 
increased painful days 
in outpatient group 
 
Construct validity was 
determined by 
comparing inpatient 
and outpatient groups; 
pain burden was 
greater in the inpatient 
group (t[127] = -5.12, 
p < 0.001)  
SCPBI-Y-  
Cronbach’s α 
 .909 O//P group;  
 .821 I/P group and 
 .891 in both, via test-
retest reliability using 
Pearson correlation 
coefficient  
 r = .80, P < 0.001 
Can be completed by 
patients and caregivers in 1 
minute 





Visual Analog Scale 
(VAS) 
 





100 participants with all 
genotypes of SCD  
 
Age groups: 3-7, 8-12, 13-
18 years 
VAS – Unidimensional 
instrument; 1 item 
scale 
Scored on a 100 mm 
pain intensity scale 
0 mm = no or least 
pain 
100 mm =“pain as bad 
as it could possibly be”  
Reported construct 
validity  r = 0.44, 0.28, 
0.44, p < 0.001 
(between parent & 
child, nurse & child, 
nurse & parent) from 
Pothmann, 1990 
Reliability, interrater 
reliability  90%; r = 
0.87; test-retest 
agreement = 29% 
Adjusted reliability = 
45%  
 
VAS - 1 item scale, simply 
and quickly administered 
to wide range of age 
groups; however, preschool 
age groups have difficulty 
using this instrument 
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67 adult participants 




Enrolled in Duke 
Comprehensive Sickle Cell 
Center 
Race not identified 
Patient or proxy marks 
the place on line 
Line is then measured 
and scored between 0 
and 100; (often 
translated to a 0-10 
rating) 
VAS p = 0.008 None reported  2 
McClellan et al., 2009 None reported 48 participants with SCD 
Ages 2-17 years 
Mean age 9.6 years 
3 age groups; 2-4, 5-9, & 
13-18 years 
24 males  
24 females  
 
Receiving venipuncture as 
part of their routine health 
maintenance visits in 
Columbia, SC  
0-100 scale. Included 
patient and  parents 
rating of patient’s pain  
Reported criterion and 
convergent validity of 
parent report of child’s 
pain using VAS: R = 
0.72, p < 0.001 from 
Varni, Thompson and 
Hansen, 1987 
Child report r = 0.33; for 
parent report of children 
(age 2-4 years) r = 0.27 
 2 
Dampier et al., 2013 None reported 38 participants (4 
withdrew) with all 
genotypes of SCD 
 greater than 10 years of 
age w/acute pain rated as > 
45 on VAS 
0-100 scale None reported  None reported Identified ease of 
administration in older 
child and adult populations 
2 
Myrvik, et al., 2013 None reported 28 participants 
Ages 8-18 years  
Mean age 14.65 years  
14 males 
14 females  
Inclusion: any genotype of 
SCD receiving analgesic 
treatment for 
uncomplicated VOC; 
English primary language 
0 = no pain -10cm 
worst possible pain 
(scale) 
None  reported Used receiver operating 
characteristics (ROC) 
curve analyses; areas 
under the curve (AUC) 
were used to assess the 
accuracy and 
discrimination of VAS 
to assess pain. VAS was 
found to be a fair 
discriminator (0.70-
0.80) 
Serial assessment using 
VAS every 30 minutes 



















100 African American 
children w/SCD 
Ages 3-18 years  
Mean age 8.52 years 
51% males 
49% females 
Divided into 3 age groups 
(Piaget cognitive periods): 




instrument; rated 0-5; 6 
pictures of faces from 
smiling face to crying 
face; pictorial scale 
used for children > 3 
years old 
Reported WBFS 
concurrent validity of 
x2 = 1.21, df = 5; from 
Wong & Baker, 1988 
in Luffy and Grove  
 
Reported r = 0.63 to 
0.94 from Keck et al. 
1996 
Interrater reliability 
90%; test re-test 
reliability 37%; adjusted 
reliability to 67% 
Reported convergent 
reliability t=.67 & p = 
.0001 from West et al., 
1994 Reported 
reliability r = 0.791 from 
Wong and  
Baker, 1996 
WBFS – 6-item scale, 










156 females  
 
Race not identified 
0-5 Faces scale 
pictorial used for 
children > 8 years of 
age 
Subjects point to the 
face picture that best 
rates the pain  
0 = no pain, 5 = worst 
pain 
None reported None reported Nurses provide WBFS in 
ED during initial triage & 
every 15-30 minutes after 
initial dose of morphine 
2 
McClellan et al., 2009 None reported 48 participants w/SCD 
Ages 2-17 years 
Mean age 9.6 years 
24 males  
24 females  
Inclusion: receiving 
venipuncture as part of 
their routine health 
maintenance visits 
WBFS pain rating 0-5; 
6 pictures of faces 
from smiling face to 
crying face 
 
Pictorial scale used for 
children > 2 years 
Referenced validity 
from Bieri, Reeve & 
Champion, 1990; 
Luffy and Grove, 2003 
Referenced  reliability 
from Wong and Baker, 
1988 
WBFS preferred method of 
assessing pain in pediatric 










The Application of Genomic Testing for Pain Management in Sickle Cell Disease 
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Purpose/Objective: This literature review evaluates the current science of personalized 
medicine for sickle cell patients with refractory pain during vaso-occlusive episodes (VOEs) 
using genetic/genomic testing.  The review intends to identify the importance of a working 
knowledge of genomics and pharmacogenomics to support safe practice, patient/family teaching, 
and advocacy.  
Literature search: An examination of pain management strategies for persons with sickle cell 
disease (SCD) serves as the basis to learn and disseminate the knowledge of the genetics, 
genomics, and pharmacogenomics (PGx) related to sickle cell pain care.  The Diffusion of 
Innovation (DOI) theory was used to assess strategies linked to innovation championing, 
colleague support, and adoption of genetic testing. 
Findings: In 2014, the National Heart Lung and Blood Institute (NHLBI) supported the work of 
an expert panel that produced a synthesis of evidence-based protocols and algorithms to direct 
emergency department (ED) clinicians in the management of patients with SCD, including those 
with VOE.  Addressing the knowledge gap in PGx will lead to linking strategies to decrease 
barriers to patient and provider understanding, as well as improve patient outcomes, develop 
comprehensive algorithms, and address reported dissatisfaction with ED care. 
Conclusion:  Genomics is an essential competency for nursing education and nursing science.  
This review seeks to expand the knowledge of PGx.  Patients with SCD who demonstrate poor 
pain control despite compliance with existing evidence-based protocols may benefit from 
genomic testing and the newly introduced Precision Medicine Initiative (PMI) in the 
management of the pain and chronic disease. 




The Application of Genomic Testing for Pain Management in Sickle Cell Disease 
Sickle cell disease (SCD) is a pleiotropic hematologic disorder affecting approximately 
100,000 Americans (Centers for Disease Control and Prevention (CDC), 2015a; U.S. Department 
of Health and Human Services [USDHHS], 2014).  One common genotype that causes red blood 
cells (RBCs) to sickle is hemoglobin SS (HbSS); in this scenario, the child inherits one sickle 
gene (S) from each parent (Anie & Green, 2012).  Sickle-shaped RBCs result from the gene 
mutation of β-globin displacing glutamic acid with valine at the 6th position of the hemoglobin 
subunit (Ballas et al., 2010: Ghatpande, Choudhary, Quinn, & Goodman, 2008).  Pain is the 
hallmark feature of SCD.  Persons with sickle cell experience acute and chronic pain syndromes 
including “acute multiorgan failure, iatrogenic pain syndromes, neuropathy, and vaso-occlusive 
episodes” (VOEs) (Ballas et al., 2010, p. 7).  The sickled cells in VOE cause obstructive 
ischemia (CDC, 2015b; Smith & Scherer, 2010; USDHHS, 2014) and tissue deprivation of 
glucose and oxygen.  Episode frequency varies from person to person (Lettre et al., 2008).  The 
painful episode can last from hours to days or longer, the complications are systemic, and there 
are intermittent and intractable VOE patterns of occurrence (Ballas et al., 2010; Ballas 2014; 
Human Genome, 2005).  The incidence of VOE varies from one to several per year depending on 
disease severity (Ballas, 2014; Brousseau, McCarver, Drendel, Divakaran, & Panepinto, 2007).  
Patients experiencing VOEs seek health care services in emergency departments (ED) and often 
require management of dehydration, infection, and severe pain by emergency medical teams (Po 
et al., 2012). 
Genotyping of persons with SCD provides information about medication 
biotransformation, which can facilitate precise, personalized health management.  Identifying 




component of the upcoming Precision Medicine Initiative (PMI) (Collins & Varmus, 2015; 
Crews, Hicks, Pui, Relling, and Evans, 2012).  The purpose of this manuscript is to advocate for 
the use of genetic testing to assist providers in personalizing treatment for sickle cell patients.  
The Diffusion of Innovation (DOI) theory can be used to inform the interpretation and 
dissemination of evidence regarding genomic testing of persons with SCD in order to ensure 
optimal treatment and patient outcomes. 
Traditional Treatment Approaches 
Po et al. (2012) reported that patients entering the ED for VOE and pain management 
benefitted when they had a healthcare team educated in the care of patients with SCD.  When the 
provider utilized a standardized pain assessment instrument, patients were assessed in a timely 
manner, and the time to analgesic administration was less than 30 minutes.  Additionally, febrile 
patients with SCD and chest pain syndromes were provided fluids and antibiotics along with 
timely vaccination of pneumonia and influenza preventatives (Po et al., 2012). 
Inadequate care for patients experiencing VOE is common. Factors such as provider 
perceptions that patients may be drug-seeking can delay prompt healthcare services.  Patient 
dissatisfaction and mistrust result when patients hear labels from their providers such as 
‘substance abuser’, ‘clock-watcher’ and ‘frequent flyer’ (Jacob, 2001; Jenerette & Dixon, 2010). 
Social, cultural, and linguistic differences can lead to inadequate care (Po et al., 2012).  Another 
factor in inadequate care for VOE includes trial and error measures to manage pain in the 
population with SCD, and divergence from care standards (Glassberg et al., 2013).  The 
treatment standards include intravenous fluids, antibiotics for bacterial infections, non-opioid, 
and opioid medications (Ballas 2014; Glassberg et al., 2013; Lottenberg & Hassell, 2005; Myers 





The search strategy for this review was developed in consultation with a research 
librarian.  A search was conducted for studies in the following databases: National Library of 
Medicine (PubMed), Ovid, EBSCO Host containing the Cumulative Index for Nursing and 
Allied Health Literature (CINAHL), and Scopus.  The following key terms were used in each of 
the databases: cytochrome P450, sickle cell, and pain.  The search of the 4 databases yielded a 
total of 82 results; 12 were retained for inclusion in this review (see Figure 1).  The exclusion 
criteria were limited to English language studies and reviews involving human samples.  In the 
PubMed search, the key terms yielded 8 studies, 2 were removed after a review of the abstracts.  
One was a study conducted on transgenic mice; the other did not contain information relevant to 
key terms and topic.  In the Ovid database, the key terms yielded 53 results, of which 50 
contained abstracts or the respective data pertained to only one aspect of the key subject matter.  
Three studies were retained.  An EBSCO Host search using the key terms yielded 7 results all of 
which were duplicates of the Pub Med search.  The Scopus search using the key terms yielded 14 
results; 6 were duplicates of the Pub Med search, 5 were not specific to the topic, and 3 were 
retained for relevance to subject. See Figure 1 for an overview of literature search. 
Genetics & Pharmacogenomics 
Persons with SCD who have genomic variations may not obtain the intended pain relief 
from opioid therapy (Yee et al., 2013).  The varying ability to metabolize and respond to the 
opioid agent is known as interindividual variability.  The genomic variations that prevent 
efficacy of opioid agents during VOE may be explained by the principles of pharmacogenomics.  
Discovery of the structure and function of genes improves predictions of the genetic effects and 




2015).  Two important genes, cytochrome P450 (CYP2D6) and UDP glucuronosyltransferases 
(UGT2B7), produce enzymes needed to metabolize opioid agents, a mainstay of VOE pain 
management (Ballas, 2014; Dabari, Minniti, Rana, van den Anker, 2008; Jimenez & Galinkin, 
2015). 
Pharmacogenetics and pharmacogenomics are synonymous terms used to describe a 
science that merges pharmacology and genomics.  For the remainder of this review, 
pharmacogenetics and pharmacogenomics will be connoted as PGx.  Nursing education that 
includes genetics and genomics at the undergraduate, graduate, and postgraduate levels prepares 
registered nurses (RNs) to function more fully in their professional roles.  Use of genomics 
contributes to health assessment, screening, management, patient/family education, and 
advocacy (Daack-Hirsch, et al., 2013).  RNs who are in graduate programs and who are planning 
to utilize prescriptive authority will improve their ability to prescribe medications safely based 
on their knowledge of the evolving PGx science (Krau, 2013).  While some clinicians may not 
take genomic variation into account during their treatment of VOE, nurses educated in genetics 
and PGx are keenly situated to address this problem (Adegbola, 2010).  They do this when they 
(a) assess SCD pain, (b) administer pain medication, (c) reassess efficacy of the pain medication 
intervention, and (d) evaluate whether the individual patient is experiencing the intended 
therapeutic effect.  The application of clinical genomics may result in utilization of a more 
appropriate therapeutic agent, optimization of health outcomes, and reduction of adverse drug 
events (Calzone et al., 2013; Krau, 2013).  A determination of proper dose and medication 
choice could be made pertinent to the patient’s human genomic biomarkers and metabolic 




To better serve patient populations with the existing scientific evidence, knowledge of 
personal genomic status is necessary through preemptive testing (Bielinski et al., 2014; Jaja et al, 
2015).  Current testing includes next generation genome sequencing assays such as, “whole-
exome or whole-genome sequencing tests and copy number variant arrays” (Evans, Burke, & 
Jarvick, 2015, p. 2259), polymerase chain reaction (PCR) (Genelex, 2014; Althea Diagnostics, 
2015; Food and Drug Administration [FDA], 2013) and single nucleotide arrays to detect 
variants of cytochrome P450 and UDP glucuronosyltransferases.  Typically, samples of buccal 
cells are collected, with results available in 48 hours (Althea Diagnostics, 2015).  Genetic 
variants affect the patient’s ability to derive the intended analgesic benefits of opioid medications 
during painful VOEs (Ballas, 2014; Genelex, 2014; Lynch & Price, 2007).  Variant labels 
include the following phenotype classifications: poor metabolizers (PM), intermediate 
metabolizers (IM), extensive metabolizers (EM), and ultrarapid metabolizers (UM) (Ballas, 
2014; Jaja, et al., 2015; Jimenez & Galinkin, 2015; Krau, 2013).  EMs are considered normal 
metabolizers, and standard dosing has been developed for the EM group.  Several studies have 
cited the serious nature of adverse reactions to medications.  In the U.S., there are 
approximately100, 000 deaths per year due to serious adverse drug reactions and a corresponding 
financial burden in the billions of dollars (Ajayi, Sun, Perry, 2000; Collins, 2010: Wilke et al., 
2007).  The information obtained from genotyping can be used to reduce adverse drug reactions 
and their associated human and economic costs to patients and society by assisting the clinician 
in making a more appropriate choice of medication and dose for pain management and other 
pathologies (Ballas, 2014; Bielinski et al., 2014; Duconge & Ruaño, 2012; Jaja et al., 2015; 




The FDA has recommended genetic testing for Warfarin, Valproic Acid, Dapsone, and 
Azathioprine therapies.  When the following chemotherapeutic agents, Cetuximab and 
Trastuzumab are prescribed, testing is required (Frueh et al., 2008).  Several medications used 
for persons with SCD  rely on the polymorphic cytochrome P450 enzyme system for 
metabolism; however, genotyping persons with SCD for CYP450 or UGT2B7 to determine the 
best opioid management is currently not approved by insurance providers (Ballas, 2014).  If 
clinicians knew the genomic status of their sickle cell patients, changes could be implemented to 
ensure that patients receive appropriate treatment (Jannetto & Bratanow, 2010; Polymorphism, 
n.d.).  Provider knowledge of each person’s genetic status associated with CYP450 has 
significance for patients by ensuring appropriate pain management and economic implications by 
decreasing inpatient hospitalizations associated with VOE (Yee, 2013). 
Adult sickle cell patients receive inadequate treatment of VOE, leading to unnecessary 
suffering (Ender et al., 2013; Jenerette & Brewer, 2010).  There are disparities in the quality of 
care delivered to SCD patients in the ED (Haywood, Tanabe, Naik, Beach, & Lanzkron, 2013; 
Jenerette & Brewer, 2010).  The incidences of inadequate care may be reduced by PGx science, 
which can help to explain why certain therapeutic agents yield poor or adverse results.  When 
sickle cell patients do not experience the intended benefits from standard opioid agents, e.g. 
Codeine and Hydrocodone, or from the nonsteroidal anti-inflammatory drugs (NSAIDs) class 
such as, Ibuprofen and Ketorolac, genotyping may explain the varied efficacies.  When a primary 
care provider has the personalized genetic information, the patient can anticipate a better 
pharmacotherapeutic response (Jaja et al., 2015), which in turn may help to decrease the reported 
dissatisfaction with ED pain control.  Knowing the patient’s CYP2D6 and UGT2B7 metabolic 




dosage, and appropriate frequency (Darbari, Minniti, Rana, van den Anker, 2008).  Because they 
require long-term pharmacotherapeutic interventions, persons with SCD will benefit from the 
impact of evolving PGx science on the development of medications pertaining to the “genetic 
determinants of treatment effects” (Zineh & Pacanowski, 2011, p.730). 
Application of Diffusion of Innovation 
Everett Rogers developed the mid-range theory, Diffusion of Innovation (DOI).  The DOI 
theory suggests that when stakeholders communicate consensus about an innovation, adoption of 
the innovation is likely to occur within regulatory guidelines.  Health system stakeholders such 
as the FDA have oversight of genetic testing (Zineh & Pacanowski, 2011).  The CDC and the 
Centers for Medicare and Medicaid Services (CMS), in collaboration with the FDA, reinforce 
the use of clinical laboratory improvement amendments (CLIA) quality control standards for 
laboratories performing genetic testing (CDC, 2015c).  The oversight of genetic testing is still 
evolving and complex, and theories like the DOI can help clarify when to use genetic testing. 
Even though Rogers may not have anticipated the scenario currently under investigation, 
DOI theory, as articulated by Rogers (2003), suggests that when stakeholders communicate the 
innovation, in this case genomic testing, consensus can result in adopting the tests.  Genomic 
analysis has yet to be implemented to ensure appropriate pain management in the population of 
sickle cell patients.  Scientific research supports further analysis and “preemptive genotyping” in 
persons with SCD (Jaja et al., 2015, p.272; Jaja, Patel, Scott, Gibson & Kutlar, 2014).  
Utilization of genomic testing and further analysis of its use may lead to personalizing treatment 





Applying the Diffusion of Innovations to Sickle Cell 
The adoption of pharmacogenomics practice by treatment centers, providers, and patients 
is an innovation that will help to remove barriers to the therapeutic effectiveness of a broad range 
of medications and demonstrate the clinical usefulness of genetic and genomic testing (Althea 
Diagnostics, 2015; Ballas, 2014; Blue Cross Blue Shield (BCBS), 2010; Calzone et al., 2013; 
Genelex, 2014; Jimenez & Galinkin, 2015; Krau, 2013).  PGx is being used on a limited basis to 
assist in prescribing medications.  To move towards the goal of personalized medicine and the 
Precision Medicine Initiative, preemptive genotyping also could be advantageous to the 
caregivers of individuals requiring long-term medication management.  Knowing the genomic 
profiles of persons with sickle cell provides clinicians with integral component to a patient’s 
health assessment.  Linking all applicable health information supports safe practice and can 
result in greater provider and patient satisfaction. Above all, such information linking can 
improve outcomes and save lives (Zineh & Pacanowski, 2011). 
The ED of hospitals is the entry point for care of patients experiencing a sickle cell crisis.  
Laboratory staff can perform genetic testing in certified laboratories by obtaining an oral swab, 
saliva, or a blood sample.  Currently, genotyping takes 48 hours (Althea Diagnostics, 2015).  
Existing care protocols can be implemented until the genomic findings return; then a more 
educated and informed approach to care can occur, which will empower providers with a broader 
understanding of patients’ needs.  The patients can receive their personal health care data via 
health educators (geneticists, nurses educated in genetics/genomics) in the system.  This 
information can become part of the electronic medical record (EMR), which will greatly assist in 
treating similar future crises.  Patients’ health needs will be improved by more targeted therapy, 




Policy change requires substantiated research evidence, as well as clinicians within the 
system who possess the knowledge and ability to influence and support stakeholders.  Leaders 
are needed who will monitor data pertaining to the innovation and promote data progress, 
maintenance, and sustainability to ensure successful dissemination and application of the system 
change (Glanz, Rimer, & Viswanath, 2008; Rogers, 2003).  Using the DOI’s system-based 
approach, Carpenter and Sherbino (2010) described change promotion in a group of physicians 
who prioritized (a) seeking opinion leaders to help change standard care and (b) incorporating a 
new care standard to promote better patient outcomes.  The researchers determined that, without 
such leadership, it may have taken 10 years to incorporate a new standard of care, even with 
authenticated evidence supporting the change. 
According to an administrator of a representative emergency department, the changing of 
emergency care policy or protocols entails a process of sufficient study that is communicated by 
evidence pertaining to best practices of healthcare professionals.  Accrediting bodies or 
established organizations such as The Joint Commission, Boards of Nursing (BON), Emergency 
Nurses Association (ENA), or other trauma coordinators organizations (TC) are influential in 
supporting the change.  A medical director and members of the ED committee communicate the 
information to a clinical operations committee for consideration before adoption occurs (V. Oge, 
personal communication, 11/21/2012). 
In addition to the complexity of creating change in the healthcare system, the patients’ 
reluctance to change can contribute to innovation complexity, e.g., individuals may have 
reservations about their genetic information becoming part of their medical record.  To help 




needed to inform patients about genetic testing and their legal protections under the Genetic 
Information Nondiscrimination Act (GINA) (Allain, Friedman, & Senter, 2012). 
Finally, use of genomic testing for optimal medication selection is considered highly 
desirable, yet still in its early stages. Such testing will provide a forum for examination, 
experimentation, data collection, and dissemination of data, thus promoting value in treatment.  
Researchers have advocated for large prospective clinical trials to determine the efficacy of 
genotyping in the clinical environment (Lynch & Price, 2007).  Pharmacogenomic testing is a 
timely scientific innovation that has significant potential to impact the public’s health and to 
improve current health assessment, treatment strategies, and outcomes.  In the United States 
(U.S.) today, there is growing support of system-wide initiatives to improve patient outcomes by 
government agencies, private institutions, and hospital organizations while also protecting 
patient and family confidentiality.  Academic institutions, insurance corporations, medical and 
government-funded research centers are participating in the dissemination of information about 
genetic testing.  However, genotyping and PGx continue to lack the substantive backing that 
could lead to better research analysis and implementation in practice (BCBS, 2010).  In order to 
reach large audiences of researchers, clinicians, administrators, and policymakers, the 
translational benefits of such testing needs to be communicated to professional associations and 
accrediting organizations.  Genetic testing is recommended or required practice in few 
circumstances despite substantial amounts of research about its use.  From a patient advocacy 
and researcher standpoint, PGx can be used by clinicians as a guide for targeted treatment rather 
than hit or miss prescriptive practices (Krau, 2013).  In a 2007 study, Brousseau, McCarver, 
Drendel, Divakaran, and Panepinto, assessed children with SCD that were unresponsive to 




additional genetic testing and alternative medication therapies were recommended for the 
treatment of sickle cell pain (2007). 
Nurses Role in Advancing the Innovation 
Nurses are in an excellent position to educate patients with sickle cell disease and the 
community about genetic variability and pharmacogenomics (Adegbola, 2009; Jenkins, Prows, 
Dimond, Monsen, & Williams, 2001; Umberger, Holston, Hutson, & Pierce, 2013).  The study of 
personalized medicine through genotyping and PGx is evolving.  The implications for nursing 
education and practice have been studied, and nurse leaders, educators, researchers, institutions, 
and healthcare organizations have advocated genetics and genomics educational standards for 
baccalaureate and graduate prepared nurses (Consensus Panel on Genetic/Genomic Nursing 
Competencies, 2009; Daack-Hirsch et al., 2013; Umberger, Holston, Hutson, & Pierce, 2013; 
Williams et al., 2011).  Various nurse scientists also have provided recommendations for 
inclusion and integration of genetics and genomics in nursing education (Daack-Hirsch et al., 
2013; Daack-Hirsch, Dieter, & Quinn Griffin, 2011; Daack-Hirsch, Driessnack, Perkhounkova, 
Furukawa, & Ramirez, 2012; Hetteberg & Prows, 2004).  An accrediting organization for 
nursing programs has endorsed genetic and genomic curriculum as essential components for 
nursing practice in the areas of diagnostics, assessment, and disease management (AACN, 2008). 
A global nursing organization, the International Society of Nurses in Genetics (ISONG), 
promotes the educational and professional development of nurses in genetics and genomics by 
holding annual conferences, providing online and text resources (ISONG & American Nurses 





Practicing nurses report the need for continuing education and the importance of having 
their professional organizations and opinion leaders as valuable resources in facilitating the safe 
integration of the evolving genetic and genomic science into nurse practice environments 
(Andrews, Tonkin, Lancastle, & Kirk, 2014; Coleman et al, 2014; Umberger, Holston, Hutson, 
& Pierce, 2013).  Recently, the National Institute of Nursing Research (NINR) convened with 
other partners to develop a plan to guide and advance genomic nursing science over the next 10 
years, with the goal of developing strong evidence to improve patient outcomes (Tully & Grady, 
2015). 
This review focuses on supporting the pain needs of persons with SCD and the benefits 
associated with genotyping.  Persons with SCD take maintenance medications for chronic pain as 
well as medications for the acute exacerbations of VOE.  PGx aids in ensuring that the right 
medication and the right dose are prescribed for the right person.  There is increasing public 
awareness about genetic and genomic science. Nurses will be called upon to interpret what the 
genetic science means.  When nurses draw upon their academic preparation and 
therapeutic communication skills to explain genetic testing and PGx, nurses fulfill their role as 
patient educators and advocates.  When individuals know their personal genomic status, they can 
be empowered to self-manage their health.  This exchange of knowledge and patient education is 
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The exacerbations of sickle cell disease (SCD) impose significant disease burden on the 
persons affected. Currently, there is an absence of sickle cell specific evidence-based practice 
guidelines addressing the psychosocial health needs in this population though studies suggests 
that these needs are significant. 
Using a quantitative approach, this study is a secondary analysis of data collected from 
adults with SCD (N = 179) in 2004 in the southeastern United States. The purpose of this 
analysis is to examine the associations of depressive symptoms (DS), self-efficacy, social 
support, coping and the coping subscale measures of spirituality with quality of life in this 
convenience sample. 
The analysis identified a statistically significant association of depression, coping, self-
efficacy and social support with quality of life in this sample. 
Guidelines inclusive of the psychosocial health issues of persons with SCD support 
caregiver efforts to provide patient-centered care.  Psychosocial health is a significant component 









 Associations of Psychosocial Measures with Quality of Life in a Sample of Adults with Sickle 
Cell Disease  
Sickle cell disease (SCD) currently affects approximately 100,000 Americans (Centers of 
Disease Control [CDC], 2011).  SCD is a genetic disorder that causes mutations to the 
hemoglobin molecules in red blood cells.  These mutations cause vascular occlusions, infarctions 
(Nussbaum, McInnes, & Willard, 2007), and other acute and chronic pathologies.  The chronicity 
and acute manifestations of the illness trigger severe recurrent pain episodes with physical and 
psychosocial debilities, including affective disorders such as depression.  In persons with SCD, 
depressive symptoms (DS) are highly prevalent, ranging from 26 - 44% in salient studies 
(Edwards et al., 2009; Hasan, Hashmi, Alhassen, Lawson & Castro, 2003; Jenerette & 
Murdaugh, 2008).  In comparison, the estimated prevalence of depression in the nation is 8% 
(CDC, 2012).  Depression exacerbates chronic illnesses like SCD by increasing disease burden 
and disability (Moussavi et al, 2007).  The incidence of suicide in the population with SCD is 
commensurate with other populations with severe chronic illness (Edwards et al., 2009), yet for 
individuals with SCD and its unique disease management requirements (e.g. pain control, health-
related stigma, anxiety), evidence-based guidelines are absent for the screening and management 
of depressive disorders (Edwards et al., 2009; Jenerette, Funk, & Murdaugh, 2005; Thomas & 
Taylor, 2002; United States Department of Health [USDH], 2002, United States Department of 
Health and Human Services [USDHHS], 2014).  Clinical practice guidelines exist for the 
management of psychiatric illnesses (APA Work Group on Psychiatric Evaluation, 2016). The 
lack of inclusion of such guidelines directly affects health management and may indirectly affect 
self-efficacy and quality of life in persons with SCD (Edwards et al., 2009; Jenerette et al., 2005; 




This study examined the psychosocial needs of a sample of adults with SCD in order to 
identify factors predictive of quality of life in adults with SCD and to make inferences pertaining 
to targeted interventions.  The purpose of this study was to identify the associations of 
psychosocial variables with quality of life by secondary analysis using the Self-Care 
Management for Sickle Cell Disease (SCMSCD) theoretical framework (Jenerette, 2004; 
Jenerette & Murdaugh 2008).  This secondary analysis of 179 respondents with SCD (Jenerette, 
2004; Jenerette et al., 2005; Jenerette & Murdaugh, 2008) offers information to establish the 
groundwork for future randomized controlled trials that provide needed evidence for the 
development of psychosocial clinical practice guidelines for comprehensive SCD care (United 
States Department of Health & Human Services [USDHHS], 2014). 
Depression is characterized as a health outcome in the Self Care Management for Sickle 
Cell Disease (SCMSCD) model (Jenerette & Murdaugh, 2008).  Blacks in the general population 
have a 10.4% lifetime prevalence of major depressive disorder (Edwards et al., 2009).  
Depression combined with chronic illnesses, like SCD, imposes additional burdens (Levenson, 
2008; Moussavi et al., 2007; National Alliance on Mental Illness [NAMI], 2009; Thomas & 
Taylor, 2002).  Chronic illnesses like SCD, combined with depression, are associated with 
decreased quality of life, self-efficacy, and health maintenance; also, susceptible individuals are 
more likely to experience a higher incidence of acute health crises (Levenson, 2008; NAMI, 
2009; Thomas & Taylor, 2002).  Providers can help patients with SCD better manage health 
complications by recognizing depressive symptoms (DS) early and facilitating prompt 
comprehensive health management (Tanabe et al., 2010). 
In the parent study (Jenerette, 2004), 26% of the participating adults with SCD self-




Inventory Fast Screen (BDI-FS) demonstrated that 29% of the 179 respondents who completed 
the BDI-FS met the criteria for DS, as indicated in Table 1.  The BDI-FS has reported approved 
psychometric ability to evaluate clinical change in patients with pain (Law, Naughton, Dhar, 
Barton, & Dabscheck, 2014; Poole, Bramwell & Murphy, 2009).  In this study, the authors used 
the SCMSCD model to examine the associations between the sample’s vulnerability factors and 
health outcomes, specifically depressive symptoms and quality of life.  People with SCD 
experience stigmatization and disparate health issues related to acute and chronic pain, chronic 
illness management, psychosocial disorders, race, and inadequate provider knowledge.  The 
patient population is in need of interventions that will facilitate provider understanding and 
support for patients’ desires for self-efficacy and quality of life (Ballas, 2010; Haywood et al., 
2009; Levenson, 2008; Tanabe et al., 2010).  Vulnerability, intrapersonal factors, self-care 
management, and health outcomes are the foundation of the SCMSCD model.  This study 
expand on the work of Jenerette (2004) by assessing DS along with self-efficacy, coping, and 
social support and its impact on quality of life. 
Research Question. How are depressive symptoms (BDI-FS), sickle cell self-efficacy 
(SCSES), coping behaviors (FCPCS), social support (MOS-SSS), associated with quality of life 
(CIQOLL) in a sample of adults with sickle cell disease (SCD)?  The following hypothesis 
guided the analyses: In an examination of depressive symptoms, quality of life will be affected 
when adjusted for disease related potential moderators self-efficacy, coping, and social support 






Data Source and Sample 
The study sample for this secondary analyses consisted of 179 African Americans with 
SCD who completed measurements for depressive symptoms and quality of life.  This sample is 
a subset of a convenience sample of 232 African Americans with SCD enrolled at two clinics 
from September 2003 through April 2004 in the southeastern U.S. to test the Theory of Self-Care  
Management for Vulnerable Populations in persons with SCD (Jenerette, 2004).  The following 
inclusion criteria guided the selection of study participants in the original study:  at least 18 years 
of age, able to read and write English, able to give consent, attending a sickle cell clinic, and 
having a diagnosis of SCD.  University IRB, clinic approval, and informed consent were 
obtained before data collection occurred.  Each of the participants received paper questionnaires 
that were completed within 45-60 minutes at one clinic visit.  Twenty-five dollars were given to 
each of the subjects for participation in the research (Jenerette, 2004; Jenerette &Murdaugh, 
2008).  One hundred seventy-nine African American respondents completed both the CIQOLL 
and BDI-FS indicating their level of quality of life and depressive symptoms and are the subjects 
of this analysis. 
Measures 
The demographic data/health need vulnerability questionnaire is a 12-item survey that 
asked about age, gender, education, employment, marital status, number of vaso-occlusive 
episodes (sickle cell crises) per year that required hospitalization, and complications (Jenerette & 
Murdaugh, 2008). 
The Family Coping Project Coping Scale (FCPCS) is a 54-item Likert-style survey 




and manages health issues.  The subscales are seeking/using social support, avoidance, spiritual 
activities, managing illness, and focusing on others.  Exploratory factor analysis was used to 
determine construct validity, and Cronbach’s alpha ranged from .71- .90, thus demonstrating 
internal consistency reliabilities.  Coping behaviors are determined by the summation of subscale 
scores, with higher scores indicating a higher coping ability. (Jenerette, 2004; Jenerette & 
Murdaugh, 2008).  Scores may range from 0 - 162.  The subscale addressing spirituality was 
specifically examined.  It contained 7 summed items with a potential scoring range of 0 – 21. 
The Medical Outcomes Study Social Support Survey (MOS-SSS) is a 19-item Likert-
style instrument that measures a person’s perceptions of support.  The four subscales are 
emotional/informational, affectionate, tangible, and positive social interaction.  Confirmatory 
and principal components analysis supported construct validity with both total and subscales 
Cronbach’s alpha of value of .91, thus establishing internal consistency reliabilities.  Higher 
summed scores indicated greater social support (Jenerette, 2004; Jenerette & Murdaugh, 2008). 
Scores may range from 19 - 95. 
The Beck Depression Inventory-Fast Screen (BDI-FS) is a 7-item scale used to screen 
individuals for DS in the clinic environment because of its conciseness.  It is an abbreviated 
version of the BDI-II and is believed to be a culturally appropriate instrument for screening 
African Americans (Dutton et al., 2004).  The BDI-FS demonstrated coefficient reliability in 
various practice settings.  The reliability coefficient of 0.84 was calculated using Cronbach’s 
alpha.  Higher summed scores on the BDI-FS indicate greater depressive symptom severity 
(Jenerette et al., 2005). Scores may range from 0 - 21. 
The Chronic Illness Quality of Life Ladder (CIQOLL) is a 28-item survey scale that 




friends, spiritual well-being, peace of mind, and overall satisfaction or quality of life (Jenerette & 
Murdaugh, 2008).  CIQOLL has demonstrated reliability and validity in measuring quality of life 
indicators in persons with chronic illness (Murdaugh, Moneyham, Jackson, Phillips, & Tavakoli, 
2006).  Cronbach’s alpha coefficients ranged from .91- .95, and internal consistency coefficients 
surpassed the standard level of .80.  A higher summed score on the CIQOLL indicates a better 
perceived quality of life (Jenerette & Murdaugh, 2008).  Scores may range from 28 - 280. 
The Sickle Cell Self-Efficacy Scale (SCSES) is a 9-item Likert-style scale that measures 
a person’s views of how they are best able to live their lives with SCD.  The scale measures the 
relationship between self-efficacy and (a) self-esteem, (b) sense of mastery, and (c) internal 
health locus of control to establish convergent validity.  Cronbach’s alpha was used to evaluate 
the internal consistency; a level of .89 was reported.  The greater the summed score on the 
SCSES, the higher the perception of a well-managed life with SCD (Jenerette & Murdaugh, 
2008).  Scores may range from 9 - 45. 
The reliability of each of the data collection instruments was determined to be .70 or 
greater, with one exception.  The FCPCS subscale (focusing on others) had a lower reliability 
(.56), using Cronbach’s alpha as a measure of internal consistency (Jenerette & Murdaugh, 
2008).  Jenerette et al. discussed conclusions and limitations of their research, which provided 
insight for this analysis (2008). 
The levels of measurement for the categorical variables sex, employment, relationship 
status, housing status and self-report depression yes/no are nominal.  Age, education, income, 
sickle cell crises per year are ordinal levels of measurement.  The levels of measurement for the 
continuous variables BDI-FS total, SCSES total, FCPCS total, CIQOLL totals, and MOS-SSS 





The level of DS as determined by the BDI-FS total score was the primary independent 
variable (IV) of interest and was analyzed as a continuous variable.  The CIQOLL- quality of life 
total score was used as the dependent variable (DV, continuous).  The research question for this 
study follows: How are depressive symptoms (BDI-FS), disease-related self-efficacy (SCSES), 
coping (FCPCS), and social support (MOS-SSS) associated with quality of life (CIQOLL) in a 
sample of adults with SCD? 
To investigate the characteristics of the study sample, univariate analyses were conducted 
for all demographic and psychosocial variables.  Tests for data normality were conducted and 
assessed using Kolmogorov - Smirnov tests and Q-Q plots.  The variables were approximately 
normal except for the number of sickle cell crises (vaso-occlusive crises) per year, and BDI-FS 
total scores, which were log transformed after adding a “1” to each score (or number of years) 
due to possible “zero” values. 
Associations of quality of life with study variables were explored in a step-wise manner.  
In step 1, bivariate associations of the effect of the demographic, clinical, psychosocial variables 
on quality of life were examined using independent t-tests, and correlation as appropriate.  
Demographic and clinical variables that showed a p-value of 0.2 or less were included in 
subsequent regression modeling along with variables known or suspected to affect quality of life 
regardless of their significance in bivariate analysis.  In a second step, multiple linear regression 
was used to investigate the association of quality of life (CIQOLL) with the primary variable of 
interest, log-transformed depressive symptoms (BDI-FS t) in combination with one additional 
psychosocial variable self-efficacy (SCSES), coping (FCPCS), spirituality (FCPS subscale) and 




of the previous models until all adjustment variables were included.  Variables were retained in 
the final model even if no statistically significant association with quality of life was observed if 
they contributed to the variance explained in quality of life in the full model.  The coping 
variable (FCPCS) in the bivariate was not statistically significant, p value .289, but was included 
in modeling due to suspected association with quality of life.  Moderation among psychosocial 
variables was investigated by including interaction terms for moderation of the effect of 
depressive symptoms on quality of life through self-efficacy, social support, coping and 
spirituality as well as interaction terms of moderation between coping and spirituality with social 
support and self-efficacy. 
Results 
In this sample of 179 African Americans, with SCD the mean age was 34.1 years. Sixty-
two percent were female, with a mean number of years of education of 12.4; 39.1% were 
unemployed and disabled, 65.9% were never married, and 72.1% lived with family.  Most 
individuals were diagnosed with sickle cell disease in their youth and reported having 2 - 3 sickle 
cell crises per year.  Fifty-two of the 179 participants or 29.1% had a BDI-FS score that met or 
exceeded the cut-point of four (Jenerette et al., 2005) indicating the likelihood of depression 
(Table 1).  Demographic and clinical characteristics displayed no statistically significant 
associations with quality of life (Table 2). 
In bivariate models, the individual psychosocial variables were statistically significantly 
associated with quality of life with the exception of coping and the spirituality coping subscale (p 
= 0.289, p = 0.257, respectively (Table 3).  Higher self-efficacy, social support and fewer 
depressive symptoms were associated with higher quality of life.  Depressive symptoms alone 




interactions were observed indicating that none of the psychosocial variables moderated the 
effect of depressive symptoms on quality of life in this sample.  Similarly no moderation effect 
was observed among the psychosocial variables (all p>0.05). 
The final multivariate model, which included all psychosocial variables as main effects, 
resulted in 39.3% of the variance in quality of life explained when combined (Table 4).  Though 
coping did not show a statistically significant association with quality of life in this model (p 
value = .316), when it was added to the final model the variance explained in quality of life (R2) 
increased from .384 without coping in the model to .393 when coping was included.  Spirituality 
was not included in the final model since it is a subscale of the coping scale and therefore 
included as part of the total score and did not show a statistically significant association with 
quality of life individually.  Sickle cell crises per year (SCC/yr.) had a statistically significant p 
value = .011; however, it was not included in the final model because it reduced the explained 
variance in quality of life.  The final model included data from 105 individuals with complete 
information for all variables.  The participants who were included in the analysis did not differ in 
terms of characteristics from those that were excluded due to missing data on one or more of the 
psychosocial questionnaires or adjustment variables except for income (M =37,207 ± 9,773 vs. 
33,900 ± 10,301; p = .036), education (M =12.64 ± 2.11  vs 11.93 ± 1.93; p = .024), and age 
diagnosed with SCD (5.24 ± 6.28 vs 8.11 ± 8.28; p = .013). 
Discussion 
The aim of this secondary analysis was to examine the psychosocial influences including 
the effect of spirituality and identify factors predictive of quality of life in the sample of 179 




systems, requiring comprehensive, patient-centered healthcare.  This healthcare includes 
screening patients with SCD for psychosocial mental health disorders. 
The level of depressive symptoms made the single strongest contribution to the variance 
explained in the dependent variable (CIQOLL) and proved to be a statistically significant 
predictor of quality of life (Table 3).  The interaction of spirituality and depressive symptoms 
approached significance, p value = .066 indicating that further research with larger study samples 
focusing on spirituality is needed. 
We hypothesized that quality of life, is affected by self-efficacy, coping, social support, 
and depression.  This hypothesis was supported by the final model consisting of psychosocial 
factors explaining 39.3% of the variability in quality of life (Table 4). 
The participants in the original study were asked to report complications of SCD; 26% of 
the sample identified depression as a condition experienced during their lifespan (Jenerette & 
Murdaugh, 2008).  Depressive symptoms measured by the BDI-FS in the sample alone 
accounted for 25.6% of the variability in quality of life.  Psychosocial characteristics, such as 
those identified clinically by the BDI-FS are modifiable and it is essential that depression is 
recognized and managed (Jenerette, Funk, Murdaugh, 2005; Jerrell, Tripathi, McIntyre, 2011).  
The benefits of treatment have far-reaching implications to the persons affected, their social 
support system, and the health system.  These benefits include improved quality of life, increased 
social engagement, and decreased health system burden. 
SCD is frequently associated with acute pain, which takes precedence over psychosocial 
treatment when patients are experiencing emergent pain needs.  Chronic pain is a significant 
concern and is associated with underlying sickle cell pathologies.  A relationship has been 




Psychosocial health management using cognitive and behavioral therapies is an important 
adjuvant to chronic pain care (Edwards et al., 2005).  Information to guide psychosocial health 
management is absent in current treatment guidelines.  The development of patient-centered 
research to address these deficits is needed.  In the interim, collaboration with psychology and 
social work disciplines in the assessment and treatment of persons with SCD to identify 
psychosocial health issues may benefit patients and providers. 
Self-efficacy consistently showed a statistically significant association with quality of life 
in the bivariate and multivariate models regardless of additional covariates in the model.  This 
implies self -efficacy is a meaningful predictor for quality of life.  An association exists between 
one’s perceptions of their ability to live life in spite of complexities (Thomas & Taylor, 2002).  
These implications statistically support that higher levels of self-efficacy associated with the 
ability to adjust to life circumstances may promote quality of life. 
No statistically significant association was observed in this sample between quality of life 
and demographic characteristics related to housing status, relationship status, and employment.  
Social support and number sickle cell crises per year were associated with quality of life in 
bivariate analyses, however, this relationship did not hold in the multivariate model.  
Nonetheless, a lack of support for the aforementioned factors may make one vulnerable 
(Jenerette & Murdaugh, 2008) and sufficient evidence exists that suggests social support and 
pain management are vital to health maintenance and quality of life in persons with SCD 
(Edwards et al, 2005; Jenerette, 2008; Lanzkron & Haywood, 2015). 
A pilot study to determine strategies that work best for clinicians and patients may be 
helpful in establishing grant funding for future research.  Further inquiry of bio-psycho-social-




as spirituality are areas for future research.  There are unidentified factors to explore since the 
model did not explain 60.7% of the variability in quality of life and further research is needed.  
Due to the nature of a secondary analysis, questions and analysis are narrowed to the data 
collected at the time of the original research.  The selection of participants from a variety of 
regions in the United States would be reflective of a more representative sample.  Despite these 
limitations, this dataset provides an opportunity for research in which new and relevant 
conclusions can be drawn to address the psychosocial needs of persons with SCD and further the 
goal of improving their quality of life. 
Conclusion.  This analysis demonstrates important associations among quality of life, depressive 
symptoms, self-efficacy, social support and coping as valuable predictors of quality of life in the 
sample of persons with SCD.  The data associated with these findings need to be confirmed in 
prospective studies, if the findings hold, interventions may be developed to benefit persons with 
SCD.  Psychosocial health management is a crucial element of each person’s overall health and 
quality of life and evidence-based guidelines inclusive of the psychosocial domains may be 
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Table 1: Demographic and psychosocial instruments N = 179 
*4 or greater cut-point for depressive symptoms 
Sample size (N) varies due to missing data  
  
 N Minimum Maximum Mean Median STD Proportion 
  DEMOGRAPHICS 
Age (yr.) 179 18 73 34.1 30.0 12.5  
Female 111      62.0% 
Education (yr.) 179 5 21 12.4 12.0 2.1  
Income ($) 170 17843 65375 35865 35424 10092  
Employment 179   .    
 Fulltime 37      20.7% 
 Part-time 18      10.1% 
 Not employed 54      30.2% 
 Not employed - Disabled  70      39.1% 
Relationship status 179       
 Married 34      19.0% 
 Divorced 12      6.7% 
 Widowed 8      4.5% 
 Separated 7      3.9% 
 Never married 118      65.9% 
Housing status 178       
 Live alone 37      20.7% 
 Live with family 129      72.5% 
 Live with friends 12      6.7% 
  CLINICAL CHARACTERISTICS 
Age Diagnosed with SCD 163 1 55 6.4 4.0 7.3  
Sickle Crises per Year (SCC) 169 0 25 2.6;  2.0 3.3  
History of Self-Reported 
Depression 
48      26.8 
  PSYCHSOCIAL INSTRUMENTS 
Chronic Illness Quality of Life 
Scale (CIQOLL) 
179 51 280 222.9     227.0 34.1 100% 
Beck Depression Inventory- Fast 
Screen (BDI-FS) 
179 0 19 2.7 
 
2.0 3.4 100% 
Medical Outcomes Study-Social 
Support Survey (MOSSSS) 
157 31 95 76.0 77.0 15.1 87.7% 
Family Coping Project Coping 
Scale (FCPCS) 
117 56 156 101.5 99.0 20.4 65.4 
Sickle Cell Disease 
Self-Efficacy Scale (SCSES) 
175 12 45 31.6 32.0 6.9 97.8 
BDI-FS Indices        
 0-3 127      71% 
 *4-6 31      17.3% 
 7-9 10      5.6% 




Table 2: Association of demographic characteristics with quality of life (CIQOLL).  N =179 
  CIQOLL 
 






     Female 











      
Age 179   .025 .764 
      
Age diagnosed with SCD 179   .014 .866 
      
Education (yrs) 179   .004 .963 
      
Employment 
     Full time Employment 
     Part time Employment 
     Not employed 

















      
Income 170   .118 .150 
      
Relationship status 
     Single, never married 
     Married 
     Divorced 
     Widowed 




















      
Housing status 
     Live alone 
     Live with family 














      





Table 3: Bivariate linear regression models investigating the association of psychosocial 
characteristics individually with quality of life. (N=179) 
















179 47.1 5.96 -7.89 <.001 -58.8, 35.3 .256 
Sickle Cell Disease 
Self-Efficacy Scale 
(SCSES) 
175 2.24 .34 6.62 <.001 1.57, 2.91 .197 
Family Coping 
Project Coping Scale 
(FCPCS) 
117 .17 .16 1.07 .289 -.142, .471 .001 
FCPCS spirituality 
subscale 




157 1.00 .15 6.62 <.001 . 702, 1.30 .215 
Sickle cell crises per 
year* 
169 -1.99 .78 -2.57 .011 -3.52, -
.462 
.032 





Table 4: Multivariate linear regression model including all psychosocial characteristics as 
independent variables and quality of life as dependent variable.  
 (Adjusted R2 = 0.393; N = 179)  










-30.74 8.09 -3.80 <.001 -46.78, -14.70 
Family Coping Project 
Coping Scale  
.13 .13 1.01 .316 -.126, .384 
Sickle Cell Disease 
Self-Efficacy Scale  




.25 .19 1.35 .180 -1.19, .628 





Figure 1. Frequency distribution of Beck Depression Inventory- Fast Screen
 
BDI-FS score of 4 - 19 indicate clinical concern. Beck Depression Inventory- Fast Screen  
BDI-FS scores 0–3 indicates minimal depression; 4–6 indicates mild depression; 7–9 indicates 
moderate depression; and 10–21 indicates severe depression Wang & Gorenstein, 2013. 








Sickle cell is an autosomal, recessive, single-gene disorder that has a 25% chance of 
being inherited by an offspring when both parents are carriers of a sickle cell gene.  This illness 
has a significant impact on the person, family and community and requires the coordination of 
preventive care, chronic disease maintenance, and acute health management from early 
childhood throughout adulthood. 
The three manuscripts of this compendium are interconnected because each focuses on 
persons with sickle cell disease as the population of interest or research sample, as well as, acute 
pain, pain management, disease chronicity, biopsychosocial characteristics of disease, disease 
burden, provider roles and collaborative care are given consideration.  Strategies that may result 
in improvements in health outcomes of persons with SCD have been identified for use by the 
communities of interest including the providers, researchers, and health systems. 
The purpose of the first manuscript was to present the findings of an integrative review 
and to evaluate the use of pain and pain instruments in persons with SCD.  The addition of the 
biopsychosocial-religiosity/spirituality (BPS-R/S) framework to the pain instruments allows for 
the holistic evaluation of persons using the pain instruments.  The use of the framework in this 
manuscript converted it from a fact-based document of pain instruments to a manuscript that 
encourages future research.  This research should examine instruments that measure the 
constructs of BPS-R/S and their relationship to pain control.  Another study that might be 
developed from this review is one that measures the relationship of services provided by 




The second manuscript reports the results of a review of genetics and genomics literature 
designed to better understand genetic variability associated with single nucleotide 
polymorphisms and pharmacogenomics.  The manuscript was written to respond to literature and 
personal reports of poor pain control and dissatisfaction with the health care experience in the 
emergency department (ED) by patients with sickle cell.  Another important aspect were 
provider reports of difficulty in managing patients with SCD who seek pain control during vaso-
occlusive crises.  Two questions guided this review.  Can the complexities of pain control be 
associated with pharmacokinetics (what the patient’s body was doing with the medication)?  
Might genetic testing be used to identify single nucleotide polymorphisms as factors in the lack 
of pain relief with traditional therapeutic agents for persons with SCD?  Training received at the 
National Institute of Health - Summer Genetics Institute provided the foundations to support the 
development of the manuscript. 
The Diffusion of Innovation framework provided a substantive and tested guide for the 
introduction of the ‘newer technology’.  Genetic testing is not widely utilized to determine a 
person’s genetic variability for prescriptive use, but this testing has substantively increased in the 
past 3-4 years.  When the first draft of this manuscript was written, few certified labs were 
advertising genetic testing for single nucleotide polymorphisms; however, by the time of this 
document’s completion, numerous laboratories were advertising directly to consumers and 
primary care providers.  Additionally, government subsidized research has increased in the study 
of the ‘omics’ resulting in an enormous amount of data for analysis.  In 2015, President Obama 
authorized a program entitled the Precision Medicine Initiative (PMI) with the purpose of 




Genetics and genomics can be integrated into nursing practice to provide patient 
advocacy, patient education, to advance human science in this technologically evolving society. 
For the ED/bedside nurse hearing a patient say that their pain is not relieved, or having a 
hypermetabolic patient slip into a coma-like state from a standardized dose of medication, 
genomics might provide an explanation.  Once there is a better understanding, practice changes 
may occur.  The changes may include policy and protocol development which may be used to 
address the various metabolic states of patients related to their genomic profiles. 
The third manuscript reports findings from a secondary analysis of a large dataset from a 
sample of research participants with SCD.  Dr. Coretta M. Jenerette collected the original data 
and tested the Theory of Self-Care Management for Vulnerable Populations and published the 
findings in her dissertation and subsequent publications.  This theory has evolved into The 
Theory of Self-Care Management for Sickle Cell Disease.  This dataset provided an opportunity 
to investigate concerns about the need for evidence-based clinical guidelines inclusive of the 
mental health needs in the sample.  The results of the secondary analysis demonstrated 
relationships between psychosocial factors and quality of life.  Depression negatively correlated 
to quality of life and proved to be the single most influential factor upon quality of life.  The final 
analysis of the model containing all of the psychosocial factors explained 39.3 % of the variance 
in quality of life. The inference can be drawn that mental health matters to quality of life.  The 
findings in this study will be used as groundwork for future research. 
Limitations 
A limitation in the development of the integrative review was the criteria that studies 
contained participants who were experiencing a vaso-occlusive crisis.  A low number of 




In addition, studies were limited to those produced in the United States.  A limitation of the 
literature review was the use of a limited number of databases and search terms.  The inclusion 
of terms of additional single nucleotide polymorphisms found in persons with SCD might have 
strengthened the evidence for genetic testing.  Limitations of the secondary analysis were 
associated with the general nature of using an existing dataset and the models used did not 
explain 60.7% of the variability. 
Future Steps 
The information in the manuscripts of this dissertation compendium provides a 
foundation for future research and may be used to improve the health outcomes of persons with 
SCD.  There is a bulleted list of potential research ideas that came from the development of the 
three manuscripts attached in Appendix C. 
Dialogues with persons with sickle cell disease and their family members continue to be 
illuminating and inspiring.  Conversations with mentors, attendance at conferences, and the SCD 
Champion Series has facilitated the forging of connections to the community of sickle cell 
providers and researchers.  A diverse body of scientific information was garnered through the 
examination of the pathology of SCD, research addressing biological, psychological, 
sociological, and spiritual issues; genomic and genetic testing, pharmacogenomics and the 
potential impact of precision medicine; analysis of a dataset that explored a rich amount of 
psychosocial information pertaining to the lives of persons with SCD.  The literature used to 
develop the three manuscripts combined to create a diverse body of scientific evidence.  This 
evidence has coalesced into foundational resources for moving forward in my roles as a 
researcher, sickle cell patient advocate, and nurse educator.  Future work includes collaborating 




patients to determine barriers to care, provide patient and family education, and to identify what 
the families need to promote their health, self-efficacy, and quality of life. 
Contribution to Nursing Science 
Nursing as a science explores the human experience through human-to-human 
interactions.  When nurses observe a problem, questions are generated and hypotheses are 
constructed.  The hypotheses are tested through analysis and experimental processes.  The 
experimentation process is scrutinized for errors before presenting the findings to colleagues and 
the community.  The creation and presentation of this dissertation are steps toward contributing 
to nursing science.  The studies in this dissertation were developed in response to seeing human 
suffering in persons with SCD and making an attempt to find ways to ameliorate the suffering 
through inquiry and the study of the existing evidence.  Biopsychosocial-religiosity/spirituality 
domains are valuable in contributing to humanistic care and may benefit persons with SCD.  
There are many opportunities for study, research, and innovation using the emerging sciences to 





Appendix A: Glossary of Genetics Content in Chapter 3 
Interindividual variability, “The interindividual variability in the response to any drug can be 
defined as "an effect of varying intensity occurring in different individuals at a specified dose of 
a drug", or as "a requirement of a range of concentrations (doses) in order to produce an effect of 
specified intensity in all of the patients" (Rocca, Dragani, & Pagliaccia, 2013, p.1). 
Pharmacokinetics (PK), “includes compliance, absorption, bioavailability, distribution, 
biotransformation” (Rocca, Dragani, & Pagliaccia, 2013, p.1). 
 Pharmacodynamics (PD), “comprising the status of drug target, resistance, tolerance; 
environment, for example interaction with xenobiotics (drugs, hormones and habits)” (Rocca, 
Dragani, & Pagliaccia, 2013, p.1). (Buxton, 2005, p.1).  
Pleiotropic, “multiple, often seemingly unrelated, physical effects caused by a single altered gene 
or pair of altered genes having multiple phenotypic expressions” (U.S National Library of 
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Appendix C: Future research ideas and topics 
Physiological  
 Diagnostic tests to measure the extent, severity, and location of tissue damage during 
vaso-occlusion. 
 Analyzing the spectrin (the fibers that create RBC flexibility) in normal versus sickled 
cells to determine differences  
 Find out the chemical and genetic influences that stimulant spectrin 
 What can be done at a genetic level to prevent the abnormal folding of RBCs? Explore 
lentivirus research (LVR) 
 Post bone marrow transplantation; (1 year, 2 years, 5 years, 10 years---long term study) 
Biopsychosocial  
 New research question: Is there a significant difference in pain control when primary 
providers in emergency departments collaborate with psychologists, social workers, and 
chaplaincy team members when they encounter a patient with SCD?  (Integrative review)  
 What are prevention strategies for transition-associated deaths in patients with sickle cell 
disease? (from Dr. Jenertte’s research) 
 What is the impact of improving the communication skills of the individual with SCD? 
(from Dr. Jenerette’s research) 
 Examine the coded data available to determine how many providers have given patients 
with SCD a diagnosis of depression during a clinic visit, admission to hospital and 
compare that with psychotropic medication prescriptions written and filled. (Discussion 
w/ Dr. Tanabe) Check for Referrals for psychotherapeutic interventions e.g. counseling, 




 Define the sequelae associated with the neurological changes associated with persistent 
pain and enhanced sensitivity to pain and determine measures to intervene and manage 
these manifestations (per Dr. Ballas’s research). 
Community-based 
 What is the relationship between persons with SCD attending support groups and self-
efficacy? 
 What is the role of the community church in the health management of members with 
SCD? 
 What data needs to be collected to create interventions that will be considered to have 
promoted culturally meaningful and comprehensive care? 
